All conditions

Oesophageal Cancer

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1901
Trials on record
374
Recruiting now
10
Australian sites
44
Phase 3 trials
4
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Oesophageal Cancer →

Get alerts when Oesophageal Cancer trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Oesophageal Cancer

Oesophageal cancer is a cancer that develops in the oesophagus, which is the muscular tube that carries food and drink from your throat down to your stomach. The cancer usually begins in the cells lining the inside of the oesophagus and can occur anywhere along its length. There are two main types: squamous cell carcinoma, which tends to develop in the upper or middle part of the oesophagus, and adenocarcinoma, which more commonly forms in the lower part, near the stomach. As the tumour grows, it can make swallowing difficult and may affect how the body absorbs nutrition.

In Australia, oesophageal cancer is relatively uncommon but serious. It is diagnosed in around 1,600 Australians each year and is more often seen in men than women. The risk increases with age, and most people diagnosed are over 60. Certain factors can raise a person's risk, including long-term reflux (sometimes called GORD), smoking, heavy alcohol use, and a condition called Barrett's oesophagus, where the lining of the lower oesophagus changes over time due to repeated acid exposure.

Treatment depends on several factors, including the type and stage of the cancer, its location, and a person's overall health. A specialist team will typically be involved in planning care. Common approaches can include surgery to remove part or all of the oesophagus, radiation therapy, chemotherapy, or combinations of these. In some cases, targeted therapies or immunotherapy may also be considered. The goal of treatment varies depending on the situation and will be discussed openly with the medical team.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Oesophageal Cancer in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Oesophageal Cancer

4 medicines listed on the PBS for Oesophageal Cancer. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 4 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Trifluridine + tipiracil Lonsurf 20/8.19, Lonsurf 15/6.14 adenocarcinoma of the stomach or gastro-oesophageal junction Metastatic (Stage IV) AU$707.14 Streamlined authority
tislelizumab Tevimbra gastro-oesophageal cancer Advanced or metastatic AU$3196.12 Streamlined authority
Trastuzumab Ogivri HER2 positive adenocarcinoma of the stomach or gastro-oesophageal junction Metastatic (Stage IV) AU$105.18 Streamlined authority
Nivolumab Opdivo oesophageal cancer or gastro-oesophageal junction cancer stage II or III AU$1972.83 Authority required

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Oesophageal Cancer currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Oesophageal Cancer.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Oesophageal Cancer by country. Australia is highlighted.

Showing the top 10 of 46 countries with trial sites.

Clinical trials for Oesophageal Cancer

Showing 376 of 376 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT02872116 · Bristol-Myers Squibb Phase 3 · 29 countries Completed
Completed Phase 3 Est. completion 27 May 2020
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇴 CO🇨🇿 CZ +21 more

Who might be able to join this trial: - You must be at least 18 years old (male or female) - You must have stomach cancer or cancer where the stomach meets the food pipe (esophagus) that cannot be removed by surgery and has spread or is at an advanced stage - You must not have received chemotherapy, radiotherapy, or bo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT03143153 · Bristol-Myers Squibb Phase 3 · 27 countries Completed
Completed Phase 3 Est. completion 18 January 2021
🇦🇷 AR🇦🇺 AU🇦🇹 AT🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇴 CO +19 more

**Who might be able to join this trial:** - You have been diagnosed with a specific type of esophageal cancer (squamous cell carcinoma or adenosquamous cell carcinoma), confirmed through a lab test of tissue - You are at least 18 years old (male or female) - Your esophageal cancer cannot be removed with surgery or trea...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT02198976 · Professor Michael Bourke Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2034
🇦🇺 AU

Who might be able to join this trial: - People who are able to give their informed consent to take part in the trial - People who are over 18 years old - People who have been diagnosed with Barrett's oesophagus (a condition where the lining of the food pipe has changed, often due to long-term acid reflux) Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT03222635 · Amsterdam UMC Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 25 July 2028
🇦🇺 AU🇧🇪 BE🇩🇪 DE🇳🇱 NL🇨🇭 CH🇬🇧 GB

Who might be able to join this trial: - People who have been diagnosed with a specific type of oesophageal cancer (called early oesophageal adenocarcinoma) that is either in the deeper layer under the lining of the oesophagus, or is a higher-risk surface-level cancer, as confirmed by a specialist digestive system patho...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT05910827 · Hummingbird Bioscience Phase 2 · 5 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇦🇺 AU Moldova🇸🇬 SG🇰🇷 KR🇹🇼 TW

**Who might be able to join this trial:** - You must be able to understand and agree to sign a consent form to participate in the study - You must be 18 years of age or older (or the age of majority in your country if that is higher than 18) - You must be relatively active and able to care for yourself, with only mild...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT05914116 · DualityBio Inc. Phase 2 · 4 countries Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇦🇺 AU🇨🇳 CN🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older with a solid tumour cancer that has spread or cannot be surgically removed, and that has continued to grow or come back after standard treatments, cannot be tolerated with standard treatments, or has no standard treatment available. - People who have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT06290505 · Australasian Gastro-Intestinal Trials Group Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 31 July 2027
🇦🇺 AU🇳🇿 NZ

Who might be able to join this trial: - You are a male or female aged 18 or older - You have been diagnosed with a specific type of cancer (adenocarcinoma or squamous cell carcinoma) of the esophagus (food pipe) or the area where the esophagus meets the stomach, confirmed by a biopsy - Your cancer has either spread to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07217938 · Peter MacCallum Cancer Centre, Australia Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2028
🇦🇺 AU

**Who might be able to join this trial:** - People who have signed a written consent form specific to this trial - People who are 18 years of age or older at the time of screening - People who received radiation therapy or chemoradiation treatment aimed at curing cancer in the throat, voice box, or surrounding areas,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07221149 · Bristol-Myers Squibb Phase 3 · 20 countries Recruiting
Recruiting Phase 3 Est. completion 8 November 2030
🇦🇷 AR🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇱 CL🇨🇳 CN🇨🇴 CO🇫🇷 FR +12 more

**Who might be able to join this trial:** - People who have advanced or metastatic stomach cancer, cancer at the junction between the stomach and oesophagus, or cancer in the lower oesophagus, confirmed through a tissue or cell sample, and who have not yet received any systemic (whole-body) treatment for their advance...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07334119 · Myeloid Therapeutics Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 January 2027
🇦🇺 AU

Who might be able to join this trial: - People aged 18 years or older - People who have been diagnosed with metastatic or advanced epithelial cancer (a type of cancer affecting the lining of organs or tissues) that has been confirmed by laboratory testing and shows a protein called HER2 on the cancer cells - People who...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07341737 · Second Life Therapeutics Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇦🇺 AU

Who might be able to join this trial: - People who are able to give written consent and understand what the study involves, including its purpose and potential risks - Adults aged 18 or older at the time of screening - People with a life expectancy of at least 3 months - People whose cancer has been confirmed by labor...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
🇦🇺 NCT07431281 · AstraZeneca Phase 3 · 22 countries Recruiting
Recruiting Phase 3 Est. completion 16 August 2029
🇦🇺 AU🇦🇹 AT🇧🇪 BE🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇷 FR🇩🇪 DE +14 more

**Who might be able to join this trial:** - You must be able to give your signed agreement to take part in the study. - You must be at least 18 years old (or the legal age of consent in your country) when you sign the consent form. - You have been diagnosed with a type of cancer called adenocarcinoma affecting the sto...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT00260559 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2050
🇺🇸 US

Who might be able to join this trial: - People who are scheduled to have a minimally invasive surgery to remove part or all of the esophagus (the tube connecting the throat to the stomach) - People who are scheduled to have open (traditional) surgery to remove part or all of the esophagus - People who have signed a for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00288119 · Case Western Reserve University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with Barrett's esophagus (a condition affecting the lining of the food pipe), confirmed by previous test results and scope examination reports. - People who have been diagnosed with adenocarcinoma of the esophagus (a type of cancer of the food pipe)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00590239 · Midwest Biomedical Research Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - People between 18 and 80 years of age. - People who are able to sign a written consent form agreeing to take part in the trial. - People who have been referred for a procedure to look at, monitor, or treat a condition in the food pipe known as Barrett's Esophagus (BE), including...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00900419 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with extensive and severe abnormal cell changes (dysplasia) in the airways of the lungs - People who do not have abnormal cell changes in the airways, recruited through a specific tissue screening project or referred by a doctor (for those with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT00991094 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇺🇸 US

Who might be able to join this trial: - You are scheduled to receive proton radiation treatment at UT MD Anderson Cancer Center - You are willing and able to sign a consent form before joining the study Who may not be able to join: - You are unable or unwilling to attend the required follow-up appointments, either at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT01684904 · Loma Linda University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - People diagnosed with a confirmed squamous cell or adenocarcinoma (specific types of cancer) of the esophagus (food pipe), affecting the middle, lower, or junction area where the esophagus meets the stomach, with possible stomach involvement of up to 5 cm. - People whose cancer h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02297217 · AHS Cancer Control Alberta Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2027
🇨🇦 CA

**Who might be able to join this trial:** - You have been diagnosed with esophageal cancer (confirmed by a biopsy). - Your cancer cannot be treated with the goal of a full cure, due to how advanced it is, whether it has spread to other parts of the body, or because of other serious health conditions you have. - You ar...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02454790 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2030
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with esophageal cancer (cancer of the food pipe) - People who are receiving a radiation therapy dose of more than 40 Gy (a unit used to measure radiation dose) Who may not be able to join: - People who do not meet all of the inclusion criteria list...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02530983 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2028
🇺🇸 US

Who might be able to join this trial: - You have had, or are currently having, surgery to remove or reconstruct your esophagus (the tube that carries food from your mouth to your stomach). Who may not be able to join: - No specific exclusion criteria were listed in the official trial information (confirm with trial si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02584244 · Lumicell, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been confirmed through a tissue sample (biopsy) to have a type of cancer called adenocarcinoma (or a related condition) in the esophagus, colon/rectum, or pancreas, and you are scheduled to have surgery or a procedure to remove the tumor. - You are at any stage of ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02634645 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with a condition called Barrett's esophagus that has developed into abnormal or pre-cancerous cell changes (dysplasia or neoplasia) - You have been diagnosed with esophageal cancer (cancer of the food pipe) Who may not be able to join: - You have a specif...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02735057 · Centre Hospitalier Universitaire de Besancon Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 16 November 2028
🇫🇷 FR

Who might be able to join this trial: - You have been diagnosed with esophageal cancer, either squamous cell or adenocarcinoma type, at a specific stage (T1-3, N0-1, M1a based on a staging system called TNM 6th edition — confirm with trial site if unsure of your stage) - You are older than 75 years of age - You are gen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT02947971 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who have previously been diagnosed with gastroesophageal reflux disease (a condition where stomach acid regularly flows back into the food pipe), also known as GERD - People aged 14 or older who have previously been diagnosed with eosinophilic esophagitis...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02972372 · The First Affiliated Hospital of Henan University of Science and Techn... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - You are of Chinese ethnicity. - You have been diagnosed with a specific type of esophageal cancer called squamous cell cancer. - Your cancer is located in the middle or lower part of the food pipe (esophagus). - Your cancer can be removed with surgery (it is considered "resectabl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT02988921 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed through a biopsy with a specific type of cancer (squamous cell carcinoma or adenocarcinoma) located in the food pipe (esophagus) or where the food pipe meets the stomach. - People whose tumor cannot be removed by surgery, or may potentially be remov...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03161522 · M.D. Anderson Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with esophageal or gastric (stomach) cancer of a specific type called adenocarcinoma, confirmed by a biopsy or tissue sample. - You have had specific scans (including a scope of the digestive tract and a PET/CT scan) to determine the stage of your can...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03183115 · E-DA Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇹🇼 TW

Who might be able to join this trial: - Adults who have been diagnosed with an early-stage oesophageal condition (such as high-grade abnormal cells, cancer in place, or a very early-stage cancer that has not spread) and who were treated with a procedure called endoscopic submucosal dissection (a technique to remove abn...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03222895 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 14 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇧🇷 BR🇨🇦 CA🇨🇳 CN🇫🇮 FI🇩🇪 DE🇬🇷 GR Hong Kong🇮🇳 IN +6 more

Who might be able to join this trial: - People diagnosed with a specific type of esophageal cancer (squamous cell or adenocarcinoma) located in the esophagus or where the esophagus meets the stomach. - People whose cancer has been assessed as removable by surgery, based on standard staging categories (confirm with tria...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03452774 · Massive Bio, Inc. Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 December 2038
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with a solid tumor cancer or a blood cancer (such as leukemia or lymphoma) - Your cancer has been tested and shows one or more specific genetic changes, protein markers, or other biological features from a large list (including markers like PD-L1, BRCA...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03712774 · Ludwig-Maximilians - University of Munich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2021
🇩🇪 DE

Who might be able to join this trial: - You have been diagnosed with esophageal cancer (a specific type confirmed by a tissue biopsy), and it has not spread to distant parts of the body (spread to lymph nodes near the collarbone is still acceptable) - You are planned to receive chemotherapy combined with radiation ther...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03731442 · Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2022
🇨🇳 CN

Who might be able to join this trial: - The cancer has come back in or near the area where it was originally treated (called a locoregional recurrence) after major surgery to remove it - The surgeon was unable to remove all of the cancer during surgery (known as a positive resection margin, or R1/R2 result) - The cance...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03734952 · Fujian Medical University Union Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2029
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a specific type of cancer cell) of the esophagus (the tube connecting the throat to the stomach), confirmed by a tissue sample analysis - People whose esophageal tumor is located in the chest area - People whose ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03801876 · NRG Oncology Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 21 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed through a tissue biopsy with a specific type of esophageal or gastroesophageal junction cancer (adenocarcinoma or squamous cell carcinoma) in the chest area - People whose cancer has been staged as Stage I through Stage IVA (but not classified...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03830801 · Massachusetts General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with Barrett's Esophagus, either now or in the past - You are over 18 years old - You are able to understand and sign a consent form agreeing to take part **Who may not be able to join:** - You are currently pregnant - You are currently taking blood-t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03916809 · University of Wisconsin, Milwaukee Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2025
🇺🇸 US

**Who might be able to join this trial:** - You have been recently diagnosed with cancer in the mouth, throat (including the back of the throat or voice box area) - Your planned treatment includes radiation therapy, with or without chemotherapy - You are 18 years of age or older and able to give your own consent to par...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03948100 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with stage I through stage IV non-small cell lung cancer (a common type of lung cancer) or esophageal cancer (cancer of the food pipe), and you are scheduled to receive at least 3 weeks of radiation treatment to the chest area. - You are well enough t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03964753 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with squamous cell carcinoma (a specific type of cancer) in the middle or lower part of the esophagus (food pipe), confirmed by scans, tissue sample, or fluid sample, and the cancer has not spread to distant parts...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04009265 · Fujian Medical University Union Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2022
🇨🇳 CN

**Who might be able to join this trial:** - People who have volunteered to take part and have signed a consent form agreeing to participate - People who have had surgery to fully remove a tumour in the chest area of the oesophagus (food pipe), with lab tests confirming it was a type of cancer called squamous cell carc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04018872 · Dallas VA Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 24 June 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with esophageal cancer that has not spread beyond the local area (meaning it has not spread to distant parts of the body) - You have been diagnosed with cancer at the junction where the esophagus (food pipe) meets the stomach, and it has not spread beyond...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04114136 · Dan Zandberg Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2032
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by lab testing of tissue or cells) with advanced melanoma, kidney cancer (renal cell carcinoma), non-small cell lung cancer, liver cancer (hepatocellular carcinoma, classified as Child-Pugh Class A only), certain bowel/solid cancers...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04117100 · Centre hospitalier de l'Université de Montréal (CHUM) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇦 CA

"Who might be able to join this trial: - People who are older than 18 years of age. - People who are scheduled for a planned, non-emergency advanced endoscopy procedure (such as removal of abnormal tissue or polyps, or treatment of certain conditions in the throat or oesophagus). - People who have read, understood, and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04135664 · Shanghai Chest Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell cancer of the esophagus (food pipe), confirmed by a biopsy - People whose lymph nodes show no signs of cancer spread, based on imaging scans - People whose cancer has been confirmed at a specific early stage (T1b) through a p...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04138212 · Henan Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 21 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with squamous cell carcinoma (a specific type of cancer) in the part of the oesophagus (food pipe) that runs through the chest, at certain stages of disease spread as classified by their medical team using the 8th TNM staging system - People whose cancer has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04278287 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years - People who have been diagnosed with a type of oesophageal (food pipe) cancer called squamous cell carcinoma that cannot be removed by surgery, confirmed through a tissue or cell sample, and at a specific stage of spread as assessed by the...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04280822 · Henan Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 2 December 2023
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed through a tissue biopsy with a specific type of esophageal (food pipe) cancer called squamous cell carcinoma, located in the chest area, at a locally advanced stage (not yet spread to distant parts of the body), as classified by a standard internati...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04306458 · University Medical Center Mainz Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 19 May 2023
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cancer (called adenocarcinoma) in the esophagus (food pipe) or where the esophagus meets the stomach, confirmed by a tissue sample test - Your cancer is considered operable (able to be removed by surgery) and has not spread to d...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04328948 · National Cancer Center, Japan Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 March 2030
🇯🇵 JP

**Who might be able to join this trial:** - People whose cancer has been confirmed by tissue testing to be a specific type of esophageal cancer: squamous cell carcinoma, adenosquamous carcinoma, or basaloid cell carcinoma. - People whose main cancer lesion is located in the chest portion of the food pipe (esophagus),...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04354064 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇺🇸 US

Who might be able to join this trial: - You must be at least 18 years old and considered a healthy donor. Who may not be able to join: - People who are younger than 18 years old are not eligible to participate as a healthy donor. Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04415853 · Sunshine Lake Pharma Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender. - People who have been diagnosed with squamous cell carcinoma of the esophagus (a type of throat/food pipe cancer), confirmed through a tissue or cell sample, including those with advanced or metastatic (spread) disease. - People wi...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04455282 · Heinrich-Heine University, Duesseldorf Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of cancer (adenocarcinoma) located at the junction where the food pipe meets the stomach (classified as type I or II), confirmed by a tissue sample analysis - People aged 18 or older - People whose general health and abilit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04460352 · Karolinska University Hospital Phase 3 · 5 countries Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇦 CA🇮🇪 IE🇳🇴 NO🇸🇪 SE🇹🇼 TW

**Who might be able to join this trial:** - You have been diagnosed with squamous cell cancer of the esophagus (food pipe) that has been confirmed by a tissue sample, and the cancer is at a locally advanced stage but has not spread to distant parts of the body. - A specialist medical team has agreed that your cancer c...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04481256 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a type of cancer) of the esophagus (food pipe) or the area where the esophagus meets the stomach, confirmed by a tissue sample test. - People whose cancer cannot be removed by surgery, as determined by scans and im...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04510129 · Cofactor Genomics, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of these specific cancers: head and neck cancer, non-small-cell lung cancer, small cell lung cancer, bladder/urinary tract cancer, stomach or stomach-esophagus junction cancer, cervical cancer, esophageal cancer, triple-negative breast cancer,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04513808 · The Cleveland Clinic Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People diagnosed with primary esophageal cancer that is believed to be contained within the esophagus and has not spread to other areas (generally referred to as Stage 1 to 3). - People who are scheduled to have esophageal cancer surgery with the goal of removing all the cancer....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04519905 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - Participants must be at least 76 years old - You must have been diagnosed with a specific type of esophageal cancer (squamous cell carcinoma), confirmed by a tissue test (pathology) - Your cancer must be at a locally advanced stage, as defined by specific staging criteria (co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04522687 · Shanghai Cancer Hospital, China Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People with a general health status rated as fully active or restricted only in physically strenuous activity (this is measured using a standard scale called ECOG Performance Status 0–1) - People who have been formally diagnosed with non-small cell...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04592211 · Yonsei University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇰🇷 KR

**Who might be able to join this trial:** - You have agreed to take part by signing a consent form - You are 19 years old or older - Your cancer can be measured or tracked using medical scans - You are generally well enough to carry out light activity and care for yourself (your doctor will assess this) - Your major or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04615013 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a confirmed type of cancer called adenocarcinoma, located in the esophagus (food pipe) or at the junction where the esophagus meets the stomach - People whose esophageal cancer is classified as stage II or stage III - People who are medica...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04652180 · Hospital Universitari de Bellvitge Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇪🇸 ES

**Who might be able to join this trial:** - People aged 18 years or older - People with a confirmed diagnosis (proven through tissue testing) of a specific type of oesophageal or gastro-oesophageal junction cancer — including adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma, or carcinoma of the gastr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04654975 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 31 March 2025
🇧🇪 BE🇫🇷 FR🇮🇪 IE🇳🇱 NL🇸🇪 SE🇺🇸 US

Who might be able to join this trial: - You had surgery for esophageal cancer between 1 January 2000 and 31 December 2019. - Your treatment involved any combination of pre-surgery treatment followed by surgery, surgery alone, or rescue surgery after other treatments. - Your cancer was identified as one of two specific...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04656041 · Massachusetts General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2024
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with cancer of the gastroesophageal junction (where the stomach meets the food pipe) or esophagogastric cancer, confirmed by a laboratory test of tissue or cells from a specific network of institutions, and the cancer must be at a certain stage...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04688801 · The Second Hospital of Shandong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2023
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with cancer of the esophagus (food pipe) or the junction between the esophagus and stomach (certain types, known as Siewert I or II), confirmed by a tissue test. - Your heart and lung health are strong enough to safely undergo surgery. - Your cancer is abl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04807673 · Tianjin Medical University Cancer Institute and Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by a tissue test - People whose cancer is located in the chest portion of the oesophagus, has not spread to distant parts of the body, and is considered s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04821778 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older - People who have been diagnosed with cancer of the oesophagus (food pipe) or the junction between the oesophagus and stomach - People whose cancer has been confirmed by a tissue sample (biopsy) as a specific cancer type (squamous cell carcinoma or ade...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04821843 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2030
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older - You have been diagnosed with cancer of the esophagus (food pipe) or where the esophagus meets the stomach - Your cancer has been confirmed by a tissue sample (biopsy) as a specific type (squamous cell carcinoma or adenocarcinoma), at a stage...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04846309 · University of Utah Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender. - People who have been diagnosed with esophageal cancer and whose doctors have recommended either pre-surgery chemotherapy combined with radiation, or chemotherapy combined with radiation as the main treatment. - People with Stage IV (...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04867590 · University Hospital, Angers Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 July 2031
🇫🇷 FR

Who might be able to join this trial: - Adults who have a condition called Barrett's oesophagus, where the lining of the food pipe has changed, measuring between 2 cm and 6 cm in length - People whose Barrett's oesophagus has been confirmed by a tissue sample (biopsy) to have low to high grade cell changes (dysplasia),...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04886635 · Bas P. L. Wijnhoven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2025
🇳🇱 NL

Who might be able to join this trial: - You have been diagnosed with a specific type of oesophageal cancer (either squamous cell carcinoma or adenocarcinoma) or cancer at the junction of the oesophagus and stomach, confirmed by a tissue test - You are due to have, or have recently had, a combination of chemotherapy and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04892849 · University of Erlangen-Nürnberg Medical School Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇩🇪 DE

**Who might be able to join this trial:** - You have been diagnosed with head and neck cancer, non-small cell lung cancer, or another type of solid tumour, and are being treated to manage the disease (not to cure it), or in some cases receiving treatment after surgery for lung cancer - Your doctor has recommended a typ...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04939051 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have a confirmed diagnosis of Barrett's oesophagus (a condition affecting the lining of the food pipe), with no abnormal cell changes, uncertain cell changes, or low-level abnormal cell changes, covering at least 2 cm of the food pipe. - People whose tissue sample...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04973306 · Shanghai Zhongshan Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2024
🇨🇳 CN

**Who might be able to join this trial:** - People whose cancer has been confirmed by laboratory testing as esophageal squamous cell carcinoma, with tissue samples taken before any treatment began - People whose esophageal tumor is located in the chest (thoracic) area - People whose cancer was staged as Stage II or II...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04986293 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with stage 3 or stage 4 lung cancer (a type called non-small cell lung cancer), esophageal cancer, or a cancer of the lymph system (lymphoma), and your doctors plan to treat it with the goal of curing the disease - You a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05028725 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
Tanzania

**Who might be able to join this trial:** *For people with suspected or confirmed esophageal cancer (Group 1):* - Adults aged 18 or older at the time of their screening visit. - People currently receiving care at Muhimbili National Hospital (MNH-Upanga or MNH-Mloganzila) in Tanzania. - People who have already had a co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05055648 · University of Aarhus Phase 3 · 8 countries Recruiting
Recruiting Phase 3 Est. completion 1 December 2027
🇧🇪 BE🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇱 NL🇨🇭 CH🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with a confirmed cancer of the food pipe (esophagus) or the junction between the food pipe and the stomach, of a specific cell type (squamous cell carcinoma, adenocarcinoma, signet cell carcinoma, or large cell carcinoma). - People who have had...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05133102 · Columbia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

**Who might be able to join this trial:** - You are scheduled for an upper endoscopy (a camera procedure to look inside your throat and stomach) or have had one within the past three years - You are 18 years of age or older - You are able to provide a saliva (spit) sample - You are able to understand and sign a consent...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05144698 · Rapa Therapeutics LLC Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older of any gender. - People whose ability to carry out daily activities is not severely limited by their illness (based on a standard medical scale called ECOG, a score of 2 or below is required). - People with an advanced, spread, or inoperable solid tum...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05173246 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old (male or female) - People who have been diagnosed with esophageal small cell carcinoma (a specific type of oesophageal cancer) that has been confirmed by a lab test, and cannot be removed by surgery, has come back, or has spread to other pa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05177133 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2025
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 or older (male or female) who are willing and able to give written consent before any screening takes place. - People with a confirmed diagnosis of stomach or gastroesophageal junction cancer (a specific type called adenocarcinoma) that has spread or cannot be...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05177393 · University of California, San Francisco Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
Kenya Malawi Tanzania

Who might be able to join this trial: - People who have been diagnosed with esophageal cancer (cancer of the food pipe), either confirmed through a tissue sample examined in a lab, or based on a clinical assessment using imaging tests or a camera examination of the food pipe (even without a tissue sample) - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05182944 · The First Affiliated Hospital of Zhengzhou University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 15 January 2024
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old, of any gender - People whose cancer has been confirmed as esophageal squamous cell carcinoma (a type of throat/food pipe cancer) through a tissue or cell sample - People who have not yet received any treatment for their esophageal cancer, and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05183126 · University of Michigan Rogel Cancer Center Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You are planned to receive a specific dose of the chemotherapy drug paclitaxel (80 mg/m², given over 1 hour by drip) - You have had a CT scan, PET-CT scan, or MRI scan (such as of the chest, abdomen, or pelvis, for any reason) within the past year that can be reviewed - You a...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05187091 · All India Institute of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 12 August 2026
🇮🇳 IN

**Who might be able to join this trial:** - People aged 18 to 69 years old - People receiving radiation therapy for squamous cell cancer of the oropharynx (back of the throat), larynx (voice box), or hypopharynx (lower throat) - People with a specific stage of cancer (not spread to distant parts of the body) that has...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05187182 · Washington University School of Medicine Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 July 2028
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by tissue or cell testing) with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be surgically removed or has spread, and the cancer is either adenocarcinoma or squamous cell carcinoma type. - People whos...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05188313 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2027
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with a type of cancer called adenocarcinoma in the esophagus (food pipe) or at the point where the esophagus meets the stomach, confirmed by a tissue sample (biopsy), and it is at a specific stage that has not spread to distant parts of the body. - Yo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05238922 · Incyte Corporation Phase 1 · 8 countries Recruiting
Recruiting Phase 1 Est. completion 27 July 2027
🇫🇷 FR🇮🇹 IT🇯🇵 JP🇳🇱 NL Puerto Rico🇨🇭 CH🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You must be 18 years old or older at the time of signing the consent form - Doctors expect you to live for more than 12 weeks - You must be relatively active and able to care for yourself, with only mild limitations on daily activity (confirm with trial site) - Your cancer must h...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05252078 · Jiangxi Provincial Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to volunteer, sign a consent form, and commit to attending follow-up appointments - People aged 18 or older - People whose general health and daily functioning is rated as fully active or restricted only in strenuous activity (confirm with trial site r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05262491 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form and follow the study plan. - People of any gender are eligible. - People aged 18 to 75 years old (for phase Ia of the study), or aged 18 and older (for phase Ib of the study). - People with an expected survival of at least 3 months. -...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05274048 · Fox Chase Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a gastrointestinal (GI) cancer (such as cancer of the esophagus, stomach, colon, bile ducts, or pancreas, or an unknown primary cancer likely from the GI tract) that cannot be surgically removed or has spread to other parts of the body - People...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05276791 · St. Antonius Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 years or older - People willing to undergo either of two types of endoscopic procedures to remove tissue (called EMR or ESD) - People who are able to give written informed consent and understand what taking part in the trial involves - People with Barrett's oesopha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05319730 · Merck Sharp & Dohme LLC Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 11 June 2027
🇧🇷 BR🇨🇱 CL🇨🇳 CN🇩🇪 DE🇮🇹 IT🇯🇵 JP🇳🇴 NO🇸🇬 SG +6 more

**Who might be able to join this trial:** - You have been diagnosed with esophageal squamous cell carcinoma (a specific type of esophageal cancer) that has spread to other parts of the body or cannot be surgically removed - Your cancer has gotten worse after receiving one previous standard treatment that included a pl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05327517 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of esophageal cancer (squamous cell carcinoma) in the neck area that can be removed with surgery, at certain stages of the disease - Your cancer may have spread upward toward the throat or downward toward the chest area - You are b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05357846 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 January 2031
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with a specific type of esophageal cancer (squamous cell carcinoma of the chest portion of the esophagus) at a stage that doctors consider potentially removable by surgery, meeting specific staging criteria (confirm with trial site) - People who have not rec...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05370144 · AHS Cancer Control Alberta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 3 February 2027
🇨🇦 CA

**Who might be able to join this trial:** - People who have been diagnosed through a biopsy with a specific type of oesophageal or stomach junction cancer (invasive adenocarcinoma of the oesophagus or gastroesophageal junction, Siewart type I–II) - People whose cancer has spread to nearby lymph nodes or grown into the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05392413 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with stage IV squamous cell carcinoma of the oesophagus (a specific type of advanced oesophageal cancer), confirmed by a tissue or cell sample, and who are planned to receive a combination of a PD-1 immunotherapy drug and a TP chemotherapy regi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05412758 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇬🇧 GB

**Who might be able to join this trial:** **AROMA 1 part of the trial:** - People aged 18 to 90 years old - People in the cancer group: those who have been diagnosed with adenocarcinoma (a type of cancer) of the oesophagus (food pipe) or stomach through a biopsy, and have not yet received any treatment for it - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05427383 · Shanghai JMT-Bio Inc. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older. - People who have been diagnosed with HER2-positive stomach cancer (including cancer at the junction of the stomach and food pipe) that has spread locally, come back, or spread to other parts of the body, confirmed by a tissue or cell sample. HER2-po...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05431738 · Société Française d'Endoscopie Digestive Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇫🇷 FR

Who might be able to join this trial: - Adults aged 18 or older of any sex - People admitted to one of the participating centres for difficulty swallowing caused by a tumour blocking the area where the stomach meets the oesophagus (food pipe), where the cancer is locally advanced or has spread to other parts of the bod...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05443841 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2024
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with esophageal cancer that has been confirmed by a tissue sample (biopsy) before starting any treatment - Your cancer is considered removable by surgery, and scans show it has not spread to distant parts of the body - Surgeons believe the cancer can b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05468008 · AdventHealth Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You are already scheduled to have a procedure called endoscopic submucosal dissection (ESD), which is a type of minimally invasive procedure done through a flexible camera to remove tissue from the digestive tract Who may not be able to join: -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05473156 · AP Biosciences Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - People who have given written consent to participate (or whose legal representative has done so) before the screening process begins. - People whose general physical functioning is rated at 0 or 1 on a standard oncology scale (meaning they are fully active or have minor rest...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05495152 · Henan Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 August 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a specific type of cancer) confirmed by a tissue biopsy. - People whose cancer is located in the middle or lower part of the food pipe (oesophagus), within the chest area. - People aged between 18 and 70 years. - P...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05504265 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You are having minimally invasive surgery to remove part of the esophagus (the food pipe) using keyhole techniques, either with a camera-guided approach or with robotic assistance - You are willing to give your informed consent to take pa...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05507411 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2024
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to sign a consent form and follow the trial schedule, including visits, treatments, and lab tests - Your physical fitness level is rated 0 or 1 on a standard activity scale (meaning you are fully active or have only minor limitations in strenuous act...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05515315 · Fuzhou General Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 May 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with localised oesophageal squamous cell cancer (a type of throat/food pipe cancer) confirmed by a tissue test, at a stage that is not suitable for surgery (either because surgery is too risky medically, or because the person has chosen not to have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05517811 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇺🇸 US

Who might be able to join this trial: - People who are 18 years of age or older - People who have recently been diagnosed by their doctor with one of the following cancers: a cancer affecting the liver, pancreas, or bile ducts; esophageal cancer; colorectal cancer; or lung adenocarcinoma (a specific type of lung cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05530343 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

**Who might be able to join this trial:** *For people already diagnosed with Barrett's esophagus (a condition affecting the lining of the food pipe) who are attending a routine check-up scope:* - People attending a routine monitoring endoscopy (camera procedure) for Barrett's esophagus with no current abnormal cell ch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05563766 · VA Office of Research and Development Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2029
🇺🇸 US

Who might be able to join this trial: - People who are able to understand and agree to participate by giving informed consent - People who have been diagnosed with esophageal cancer (either squamous cell or adenocarcinoma type) or cancer at the junction of the esophagus and stomach, where a surgeon has determined the c...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05621889 · Centre hospitalier de l'Université de Montréal (CHUM) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2026
🇨🇦 CA

**Who might be able to join this trial:** - Adults aged 18 or older who have been diagnosed with a head or neck cancer - People whose treatment plan includes both chemotherapy and radiation therapy, with the goal of curing the cancer - People whose radiation therapy plan involves a dose of at least 60 Grays (a unit use...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05624099 · Fujian Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to give written consent and take part voluntarily - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by laboratory testing, and whose cancer is at an advanced or limited-spread sta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05642338 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇳🇱 NL

**Who might be able to join this trial:** - Adults aged 18 years or older - People with Barrett's oesophagus (a condition affecting the lining of the food pipe) where the affected area meets specific size requirements — either spreading around at least 2 cm of the food pipe with a total length of no more than 18 cm, o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05677490 · Alliance for Clinical Trials in Oncology Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 8 November 2028
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People diagnosed with a specific type of cancer called adenocarcinoma (confirmed by a tissue sample) that is HER2 negative, located in the esophagus, the junction between the esophagus and stomach, or the stomach, and where the PD-L1 CPS score is known before joining (any sc...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05688176 · University Hospital, Ghent Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2027
🇧🇪 BE

**Who might be able to join this trial:** - People diagnosed with Barrett's Esophagus (a condition affecting the lining of the food pipe) where the affected area is longer than 3cm, or people with a confirmed diagnosis of a type of food pipe cancer called esophageal adenocarcinoma - People who are mentally able to und...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05698992 · Region Skane Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇸🇪 SE

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with cancer of the esophagus (food pipe) or stomach - You live in Southern Sweden, in the region called Skåne - You are scheduled to have surgery with the aim of curing your cancer at Skåne University Hospital Who may no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05704530 · Universitaire Ziekenhuizen KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2028
🇧🇪 BE

**Who might be able to join this trial:** - You are over 18 years old (male or female) - You have been newly diagnosed with cancer of the esophagus (food pipe), confirmed by a tissue sample to be either squamous cell carcinoma or adenocarcinoma (the two most common types) - Your cancer is at a stage that is considered...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05705492 · OHSU Knight Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are willing to sign a consent form agreeing to take part in the study - You are 18 years of age or older - You have been diagnosed with advanced or spread-to-other-areas esophageal, stomach, liver, pancreatic, bile duct, colorectal, or lung cancer, confirmed by a tissue...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05706558 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer — either adenocarcinoma or squamous cell carcinoma — confirmed by a tissue sample analysis, and who are having surgery to remove the oesophagus. - People whose cancer has been classified by path...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05738421 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 October 2026
🇮🇹 IT

Who might be able to join this trial: - The person must be older than 18 years of age - The person must have a specific size of breathing tube in place (5.0 mm inner diameter and 9.4 mm outer diameter) - The person must have been able to tolerate having their breathing tube capped (blocked off) for nearly 48 hours with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05738434 · The First Affiliated Hospital of Zhengzhou University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any sex - People who have been diagnosed with esophageal squamous cell carcinoma (a type of throat/food pipe cancer) confirmed by laboratory testing, where the cancer cannot be surgically removed and is either locally advanced, has returned, or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05740995 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2023
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a specific type of cancer) of the esophagus (food pipe), confirmed by a tissue test - People whose esophageal tumor is located in the chest area - People whose cancer is at a specific stage before treatment — broad...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05745857 · University Medical Center Groningen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with Barrett's esophagus (a condition affecting the lining of the food pipe), either without any abnormal cell changes, or with suspected or confirmed abnormal cell changes ranging from mild to severe, or with an early-stage cancer in the food pipe - Y...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05753748 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2029
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been diagnosed with Barrett's oesophagus, where a camera examination of the food pipe shows a specific salmon-coloured lining of at least 1 cm in length, and tissue samples from that area show particular cell changes (...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05760391 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old and are generally able to carry out daily activities with little or no limitation. - You have been diagnosed with esophageal squamous cell carcinoma (a type of esophageal cancer) that cannot be removed by surgery, has come back, or has spr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05775419 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 70 years old (any gender) who are able to drink liquids - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by a tissue test - People whose cancer has been assessed as not suitable f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05775939 · Thomas Jefferson University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are willing and able to sign and date a consent form agreeing to take part - You are willing to follow all study requirements and are available for the full length of the study - You are male or female, aged 18 or older - Your doctor expects you to live for at least 3 mon...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05780684 · Dartmouth-Hitchcock Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People diagnosed with colorectal cancer or other gastrointestinal cancers (including cancers of the stomach, oesophagus, appendix, small bowel, or ampulla) that have spread or cannot be surgically removed - People who have had appropriate body scans (che...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05799274 · Radiopharm Theranostics, Ltd Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older when you sign the consent form. - You must be willing and able to understand and sign a consent form agreeing to take part. - If you have cancer, you must have a confirmed diagnosis of one of these cancer types: pancreatic cancer (PDAC),...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05800054 · The First Affiliated Hospital with Nanjing Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to agree to the trial conditions in writing and are able to follow the treatment plan and attend follow-up appointments - People aged between 18 and 75 years old (any gender) - People who have been diagnosed with esophageal squamous cell carcinoma (a s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05818072 · E-DA Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇹🇼 TW

**Who might be able to join this trial:** - Adults who have been diagnosed with a condition where the lining of the esophagus (the tube connecting the throat to the stomach) has changed to a different type of tissue (sometimes called columnar-lined esophagus or Barrett's esophagus) **Who may not be able to join:** - P...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05862792 · Geisinger Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 years or older - People of any gender - People who are scheduled to have a type of throat or mouth surgery performed by a robot through the mouth (called transoral robotic surgery) - People who are able and willing to give their consent to participate Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05865002 · Aurigene Discovery Technologies Limited Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2027
🇮🇳 IN

**Who might be able to join this trial:** - You are 18 years of age or older - You are generally able to carry out daily activities with little or no limitation (your doctor can confirm this based on your activity level) - Your blood counts, liver function, and kidney function meet certain minimum levels as measured b...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05865743 · Radboud University Medical Center Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 31 December 2027
🇧🇪 BE🇳🇱 NL

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of esophageal cancer (adenocarcinoma or squamous cell carcinoma) located in the middle or lower part of the esophagus, or at the point where the esophagus meets the stomach, and who are scheduled for surgery to remove the e...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05875870 · Taipei Veterans General Hospital, Taiwan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 May 2028
🇹🇼 TW

**Who might be able to join this trial:** - You have been recently diagnosed with lung cancer or esophageal cancer for the first time, and it is at stage one, two, or three. - You are at least 20 years old. - You are able to speak and understand Mandarin Chinese or Taiwanese. - You are able to read and write, and do no...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05894369 · Renmin Hospital of Wuhan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years old - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by a pathology test, at clinical stage II to IVA - People who have received pre-surgery treatment combining chemo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05919030 · Renmin Hospital of Wuhan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed through laboratory testing of a tissue sample. - People whose cancer cannot be removed by surgery and has either spread to other parts of the body,...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05937438 · Anhui Provincial Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2025
🇨🇳 CN

Who might be able to join this trial: - People between 18 and 75 years old. - People who have already had surgery to remove part or all of their oesophagus (the tube connecting the throat to the stomach). - People whose tissue sample from surgery confirmed a specific type of cancer called squamous cell carcinoma. - Peo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05952661 · Hebei Medical University Fourth Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇨🇳 CN

Who might be able to join this trial: - People aged between 18 and 75 years (both men and women, with an aim for roughly equal numbers of each). - People who have been diagnosed with stage II or III squamous cell cancer of the oesophagus (a specific type of oesophageal cancer), confirmed by tissue testing, and whose ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05954312 · Vividion Therapeutics, Inc. Phase 1 · 3 countries Recruiting
Recruiting Phase 1 Est. completion 31 August 2030
🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People who have a solid tumour (cancer) that has spread to other parts of the body or cannot be removed by surgery, confirmed by a laboratory test on a tissue or cell sample. - People whose cancer can be measured on scans according to a standard set of medical criteria (RECI...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05954702 · Instituto do Cancer do Estado de São Paulo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇧🇷 BR

Who might be able to join this trial: - You have been diagnosed with cancer of the esophagus (the tube that connects your throat to your stomach) - You are able to understand what is involved and cooperate during the treatment process Who may not be able to join: - You have previously had surgery to remove all or part...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05965479 · University of Southampton Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 March 2026
🇬🇧 GB

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of stomach cancer (adenocarcinoma) of the stomach, the area where the stomach meets the oesophagus, or the lower oesophagus (a specific subtype called Type I Siewert), at an early-to-intermediate stage (not yet spread), and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05967910 · Second Xiangya Hospital of Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 to 75 years old - People who have been diagnosed with esophageal cancer confirmed by laboratory tissue testing - People for whom tumor tissue samples can be collected - People who have at least one measurable area of cancer that can be tracked using standard imagin...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05978193 · Shanghai Chest Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older - People who have been diagnosed through a tissue test (pathology) with squamous cell carcinoma of the oesophagus that has spread to other parts of the body (stage IVB, M1) - People whose general health and ability to carry out daily activities falls withi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05983432 · SystImmune Inc. Phase 1 · 5 countries Recruiting
Recruiting Phase 1 Est. completion 31 December 2026
🇫🇷 FR🇮🇹 IT🇯🇵 JP🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older who have voluntarily agreed to take part and follow the study requirements - People of any sex - People with a life expectancy of at least 3 months - People with advanced or metastatic cancer that cannot be cured, originating from epithelial tissue —...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05984342 · Affiliated Cancer Hospital of Shantou University Medical College Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - Be between 18 and 70 years old - Have not received any treatment before surgery, such as radiation therapy, chemotherapy, targeted therapy, or immunotherapy - Have been diagnosed through a tissue biopsy with a specific type of esophageal cancer (squamous cell carcinoma) in th...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06006650 · Tang-Du Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2031
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by a tissue test - People aged between 18 and 75 years old - People whose cancer is at clinical stage II, III, or IVa - People who have not previously had any...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06008054 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old - People of any gender - People who have locally advanced or metastatic gastrointestinal cancer, such as esophageal cancer, gastric cancer, or colorectal cancer - People whose life expectancy is at least 3 months - People who are willing to sig...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06019455 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, or esophageal cancer - You are planned to receive a full course of treatment combining chemotherapy and radiation therapy, with or without immunotherapy - You are betwe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06022861 · Shandong Boan Biotechnology Co., Ltd Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form agreeing to take part in the study. - People aged 18 to 75 years old, male or female. - People whose cancer has been confirmed by a laboratory test (tissue biopsy) to be squamous cell carcinoma of the oesophagus (food pipe). - Peo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06033976 · Carol Davila University of Medicine and Pharmacy Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2031
🇷🇴 RO

Who might be able to join this trial: - You have a pre-cancerous growth (such as an adenoma or abnormal tissue) in the lining of your esophagus (food pipe), stomach, small intestine (duodenum), or large intestine (colon or rectum) - You have a non-glandular type of growth (such as a neuroendocrine tumor) in the lining...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06037902 · Sheba Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2027
🇮🇱 IL

**Who might be able to join this trial:** - People who have been diagnosed with cancer that has a tumour in the oesophagus (food pipe), including tumours at the point where the oesophagus meets the stomach - People who are 18 years of age or older - People who are planned to receive radiation therapy as part of their...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06047379 · Neonc Technologies, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 February 2027
🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older. - You must be able to understand and willing to sign a written consent form. - You must have been on a stable or decreasing dose of steroids for at least 5 days before signing the consent form. - Any side effects from previous cancer treatmen...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06056336 · Guo Xufeng Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2024
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part, sign a consent form, attend follow-up appointments, and follow the study plan throughout the trial - People who have been confirmed by tissue testing to have squamous cell carcinoma of the esophagus, with the tumour located in the chest (...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06061146 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2024
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part and attend follow-up visits - People aged 70 years or older, of any gender - People who have been confirmed by tissue testing to have locally advanced squamous cell cancer of the oesophagus (food pipe) at specific stages, as classified by medic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06067438 · OHSU Knight Cancer Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are scheduled to have a minimally invasive esophageal (food pipe) surgery for cancer, abnormal cell changes in the food pipe, or problems with how the food pipe moves food - People who are 18 years of age or older - People who are able to understand the study and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06070376 · Instituto do Cancer do Estado de São Paulo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 26 February 2026
🇧🇷 BR

**Who might be able to join this trial:** - You have been diagnosed with advanced cancer of the esophagus (the tube connecting your throat to your stomach), whether or not you are currently receiving chemotherapy or radiation therapy - You have significant difficulty swallowing (rated above a certain level of severity)...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06071845 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** **As a "case" participant (people with known or suspected Barrett's esophagus):** - People between 18 and 90 years old - People who have a Barrett's esophagus segment of at least 1cm as seen during a scope procedure, or a note of suspected Barrett's esophagus in their medical...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06077981 · Instituto do Cancer do Estado de São Paulo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2024
🇧🇷 BR

Who might be able to join this trial: - People who are 18 years of age or older - People who have a early-stage (superficial) cancer of the food pipe (esophagus), either a type called adenocarcinoma or squamous cell carcinoma, where a specialist team of doctors has recommended a specific removal procedure called ESD (e...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06084897 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 26 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been confirmed through biopsy or cell testing to have squamous cell carcinoma (a specific type of cancer) of the esophagus (the food pipe), either at an advanced stage (Stage IVb) or that has come back after previous t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06086457 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 28 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been diagnosed with squamous cell carcinoma of the esophagus (a specific type of esophageal cancer), confirmed through a tissue or cell sample, at an advanced stage (Stage IVb) with cancer that has spread to no more th...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06112704 · Hansoh BioMedical R&D Company Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 years or older. - People who have been diagnosed (confirmed by laboratory testing of tissue or cells) with relapsed, locally advanced, or metastatic esophageal cancer, or other advanced solid tumours. - People who have at least one tumour that can be measured...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06116019 · Charite University, Berlin, Germany Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 October 2026
🇩🇪 DE

Who might be able to join this trial: - You must be an adult (over 18 years old) - You have any type of cancer or tumor that your doctor has recommended treating with radiation therapy and/or a combination of chemotherapy and radiation therapy - You are willing and able to sign a consent form agreeing to take part in t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06123338 · Memorial Sloan Kettering Cancer Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older at the time of signing the consent form - People with a good general health and activity level (able to carry out normal daily activities with little or no limitation, based on a standard medical scoring scale) - People diagnosed with HER2-positive cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06136845 · Rambam Health Care Campus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇮🇱 IL

**Who might be able to join this trial:** - You are a cancer patient who has had a surgery sample stored at the Rambam Pathology Department - You have given written permission for your samples and information to be collected, stored, and used for future research through Rambam BioBank or Midgam - You have been diagnose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06138028 · Qingdao Central Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with Stage IV squamous cell carcinoma (a specific type of cancer) of the esophagus (the tube connecting your throat to your stomach) - Doctors expect you to live for at least 3 months or more - You have at least one tumor that can be measured on a sca...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06161818 · Erasmus Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2029
🇳🇱 NL

**Who might be able to join this trial:** - People diagnosed with a specific type of cancer (adenocarcinoma) of the oesophagus (food pipe) or the junction between the oesophagus and stomach, at a stage where the cancer has spread to nearby lymph nodes but not to distant parts of the body, and where surgery to remove t...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06169163 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 November 2026
🇬🇧 GB

Who might be able to join this trial: - People who have been newly diagnosed with a type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue biopsy, and have not yet received any treatment for it. - People who have recently had or are currently having a camera examination of the uppe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06173986 · Shanghai Chest Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years - People whose general health and ability to carry out daily activities meets a specific standard (rated 0 or 1 on a scale used by doctors to measure this) - People whose cancer stage falls within a certain range based on how far the cance...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06181656 · M.D. Anderson Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 July 2027
🇺🇸 US

**Who might be able to join this trial:** - You are currently receiving, planning to receive, or have recently finished chemoradiation treatment using proton therapy for esophageal cancer (Group 1A). - You are currently receiving, planning to receive, or have recently finished chemoradiation treatment using a type of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06187597 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma (a specific type of cancer) of the esophagus (food pipe), confirmed by a tissue biopsy. - People whose cancer is locally advanced (has grown in the area around the esophagus) but has not spread through the bloodstre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06189898 · Sebastian Zschaeck Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2029
🇩🇪 DE

Who might be able to join this trial: - People diagnosed with a specific type of esophageal cancer (squamous cell, undifferentiated, or adenocarcinoma) at a mid-to-advanced stage (UICC stage II to IVA, up to a certain tumor size called T4a). - People with a general health and activity level rated as reasonably function...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06190639 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have signed an informed consent form agreeing to take part in the study - People with a confirmed diagnosis of thoracic (chest area) esophageal squamous cell cancer, staged as T1-3N+M0 (meaning the cancer has spread to nearby lymph nodes but not to distant parts o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06190782 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 27 September 2025
🇨🇳 CN

Who might be able to join this trial: - People aged 18 or older - People who are relatively well and able to carry out daily activities with little or no limitation (as measured by a standard health scale called ECOG, scored 0 or 1) - People diagnosed with a specific type of oesophageal (food pipe) cancer called squamo...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06192771 · University Health Network, Toronto Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇦 CA

Who might be able to join this trial: - People who have been newly diagnosed with tongue cancer at stage T2 or higher, who are scheduled for surgery to remove part of the tongue and have a tissue flap used to rebuild the area, and where the medical team expects them to be able to eat and drink on their own after surger...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06194734 · Beijing Konruns Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, male or female - People whose cancer has been confirmed by laboratory testing (biopsy or cell sample) to be squamous cell carcinoma of the esophagus or the junction between the esophagus and stomach - People whose esophageal squamous cell carcinom...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06203600 · National Cancer Institute (NCI) Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced or inoperable stomach, gastroesophageal junction, or esophageal cancer (a type called adenocarcinoma) that cannot be surgically removed - People whose cancer tissue has tested positive for a protein called PD-L1, with a score of 1...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06232083 · Anhui Provincial Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, have signed a consent form, and are willing to attend follow-up appointments - Adults aged 18 to 75 years old (both ages included), of any gender - People who have been diagnosed with esophageal cancer, lung cancer, or cervica...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06248411 · Kyowa Kirin Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 October 2029
🇯🇵 JP

**Who might be able to join this trial:** - You must be 18 years of age or older at the time of signing the consent form - You must have given written agreement (informed consent) to take part in the study - Your cancer must not have responded to standard treatments, or standard treatments are not available, or you ca...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06265285 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 or older who have a cancer diagnosis confirmed by laboratory tissue analysis, for which intravenous nivolumab has been approved by the FDA, and whose cancer doctor has recommended starting or continuing single-agent nivolumab treatment — with a willingness to...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06272214 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and willingly sign a consent form before any study procedures begin. - People aged 18 to 75 years old at the time of signing the consent form. - People who have a general health and activity level rated as reasonably functional, based on sta...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06298916 · Lantheus Medical Imaging Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2025
🇺🇸 US

**Who might be able to join this trial:** *Part 1 (for patients with metastatic sarcoma):* - You are 15 years old or older (if you are 15–17 years old, you must weigh at least 55 kg/121 lbs) - You have been diagnosed with a type of sarcoma (a soft tissue or bone cancer) that has spread to other parts of the body, conf...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06304350 · Tongji University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with resectable stage cII or cIII esophageal squamous cell carcinoma (a specific type of esophageal cancer), classified using the 8th edition international staging system - People who have not yet received any anti-cancer treatment for esophageal squamous ce...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06324357 · Boehringer Ingelheim Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 8 January 2029
🇧🇪 BE🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇰🇷 KR🇪🇸 ES +2 more

**Who might be able to join this trial:** - People aged 18 or older (or the legal age of consent in their country) at the time of signing the consent form. - People with a confirmed diagnosis of HER2-positive metastatic breast cancer, or metastatic cancer of the stomach, gastroesophageal junction, or esophagus (for mo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06329869 · National Taiwan University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇹🇼 TW

**Who might be able to join this trial:** - You are 18 years of age or older and can understand and sign a consent form - You have been diagnosed with a specific type of esophageal cancer called squamous cell carcinoma, confirmed by a tissue test - Your cancer cannot be surgically removed, has come back, or has spread...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06339060 · Ruijin Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue test, that is at a stage considered surgically removable and has not spread to distant parts of the body. - People whose general physica...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06339619 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any sex) - You have been diagnosed with esophageal squamous cell carcinoma (a specific type of esophageal cancer) that has been confirmed by a tissue or cell sample, and the cancer cannot be surgically removed or has spread to other parts...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06343597 · Methodist Health System Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with esophageal cancer (cancer of the food pipe/swallowing tube) Who may not be able to join: - People who do not have a diagnosis of esophageal cancer Important: Always verify eligibility with the trial site directly before applying.

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06346054 · KU Leuven Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2029
🇧🇪 BE

**Who might be able to join this trial:** - People who are over 18 years old - People who have Barrett's esophagus (a condition affecting the lining of the food pipe) or gastro-esophageal cancer (cancer of the stomach or food pipe) that has not yet been treated, at any stage from I to IV - Healthy volunteers who are wi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06354140 · Daping Hospital and the Research Institute of Surgery of the Third Mil... Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 May 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any gender) - You have been diagnosed with squamous cell carcinoma (a type of cancer) of the esophagus (food pipe) and received immunotherapy combined with chemotherapy before surgery (and radiation therapy was not part of your treatment p...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06354218 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part, have signed a consent form, are able to follow the study requirements, and are willing to attend follow-up appointments - People aged 75 or older, of any gender - People who have been confirmed by tissue testing to have locally advanced s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06354530 · Army Medical Center of PLA Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, at a stage where surgery is considered possible, confirmed by a tissue or cell sample test - People who are able to swallow and take anlotinib capsules by mouth - People w...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06354959 · Nova Scotia Health Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇦 CA

Who might be able to join this trial: - You have been diagnosed with lung or esophageal cancer - Your surgery is scheduled to take place at least 2 weeks from now - Your surgeon has given approval for you to take part - You are able to read and write in English - You are over 18 years of age Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06356688 · Sun Jing Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People diagnosed with squamous cell cancer of the esophagus (food pipe) in the chest area, confirmed by a tissue test (biopsy) - People whose cancer has not spread to distant parts of the body, and whose cancer is considered ad...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06361043 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2027
🇨🇭 CH

Who might be able to join this trial: - People who have given written consent to participate - People who have a confirmed diagnosis (based on tissue testing) of a specific type of oesophageal cancer (adenocarcinoma or squamous cell carcinoma) located in the chest area of the oesophagus or at the junction where the oes...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06364553 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇳🇱 NL

Who might be able to join this trial: - People who have difficulty swallowing because of a cancerous blockage in the food pipe (esophagus) or where the food pipe meets the stomach, including blockages caused by a tumour pressing from outside, or cancer that has come back after previous food pipe surgery - People whose...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06366828 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2025
🇳🇱 NL

Who might be able to join this trial: - People who have a tumor in the esophagus (the tube connecting the throat to the stomach) that has been confirmed or is suspected to be esophageal cancer - People who had a generally good level of physical functioning at the time of treatment (rated 0–2 on a standard health scale...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06380816 · Cancer Research UK Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2029
🇬🇧 GB

**Who might be able to join this trial:** - People who have given written, signed, and dated consent and are able to follow the trial's treatment and check-up schedule - People who have been diagnosed (confirmed by lab testing of tissue or cells) with an advanced solid tumour that has stopped responding to standard tr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06385717 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with esophageal cancer and a procedure called endoscopic submucosal dissection (a type of minimally invasive procedure to remove tissue) has confirmed the cancer is at an early stage (specifically pT1a-MM or pT1b). - You do not have any serious medical rea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06385730 · Shanghai Chest Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2025
🇨🇳 CN

Who might be able to join this trial: - People who have given written consent and agreed to take part in the study voluntarily. - People whose esophageal cancer has been confirmed as squamous cell carcinoma through a tissue or cell sample test. - People whose cancer is located in the chest portion of the esophagus and...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06387004 · Hopital Forcilles Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 February 2026
🇫🇷 FR

Who might be able to join this trial: - People who have been admitted to Hôpital Forcilles to receive radiotherapy for head and neck cancer - A trained ultrasound operator must be available at the time of the appointment - People who are at least 18 years old at the time of joining the trial - People who are members of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06393140 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been newly diagnosed with esophageal cancer that has not spread to distant parts of the body - Your cancer type has been confirmed by a lab test to be squamous cell carcinoma (a specific type of esophageal cancer) - You have already received or are planned to receive...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06403878 · Sichuan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 May 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 70 or older (for those aged 80 or older, the trial doctor will assess each person's situation individually to decide whether inclusion is appropriate) - People with a good general health and activity level, rated 0–1 on a standard scale, and scoring 14 or above o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06408116 · University Hospital Heidelberg Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇩🇪 DE

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer — either adenocarcinoma or squamous cell carcinoma — confirmed by a laboratory tissue test, including certain tumours where the food pipe meets the stomach (AEG I and AEG II) - People for w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06408584 · Anhui Provincial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years of age or older (any gender) - You have signed an informed consent form agreeing to take part - You are well enough to carry out basic daily activities (rated 0–2 on a standard activity scale used by doctors) - You have been diagnosed with squamous cell carc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06410651 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of esophageal cancer called squamous cell carcinoma, confirmed by a tissue sample (biopsy) - After receiving 2 to 4 rounds of initial chemotherapy (with or without immunotherapy), your cancer either stayed the same, grew only in th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06413342 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been confirmed by tissue or cell testing to have squamous cell carcinoma of the esophagus, at a stage classified as Stage II through IVb (including certain tumour and lymph node combinations, or spread limited to lymph nodes near the collarbone). - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06414902 · M.D. Anderson Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 October 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older. - People who have locally advanced cancer of the esophagus (the tube connecting the throat to the stomach). - People who have a confirmed esophageal cancer tumor larger than 2 cm that has not yet been treated, and who are planned to r...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06420258 · Fujian Provincial Hospital Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People whose condition involves early-stage squamous cell cancer or high-grade abnormal cell growth (a pre-cancerous condition) located in the upper part of the food pipe (esophagus) - People whose scans and internal camera examinations show no signs that the cancer or abnormal c...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06421376 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 80 years old - You have been diagnosed with esophageal squamous cell carcinoma (a specific type of esophageal cancer), confirmed by a tissue sample/biopsy - Your cancer is at a locally advanced stage, meaning it may have spread to nearby lymph nodes, in...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06429839 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of esophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue sample test. - You have not received any treatment for your esophageal cancer yet. - You are able to carry out normal daily activities to a reas...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06430346 · H. Lee Moffitt Cancer Center and Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with esophageal cancer in the local or nearby area (confirmed by a tissue sample/biopsy) - Your doctor rates your general health and ability to carry out daily activities as reasonably good (on a standard scale used by doctors) - Your treatment plan in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06430658 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - The cancer has been confirmed by a tissue sample (biopsy) as squamous cell carcinoma of the esophagus, with no other cancer cell types present. - The cancer is located in the chest portion of the esophagus. - No previous cancer treatment of any kind has been received, includ...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06435286 · Baylor College of Medicine Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 March 2027
🇧🇷 BR🇺🇸 US

Who might be able to join this trial: - People who are attending a routine screening procedure using a special dye (called Lugol's solution) to check for a type of cancer called squamous cell neoplasia in the esophagus (food pipe). - People who have a history of head or neck squamous cell cancer, or who have risk facto...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06440174 · University Hospital Southampton NHS Foundation Trust Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇬🇧 GB

Who might be able to join this trial: - People aged 16 or older who have been newly diagnosed with oesophageal cancer confirmed by a biopsy - People whose cancer is located in the oesophagus (food pipe) or at the point where the oesophagus meets the stomach - People who have already had CT and PET-CT scans as part of t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06445972 · Merck Sharp & Dohme LLC Phase 2 · 11 countries Recruiting
Recruiting Phase 2 Est. completion 9 May 2028
🇧🇷 BR🇨🇱 CL🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇴 NO🇰🇷 KR +3 more

**Who might be able to join this trial:** - People who have been diagnosed with stomach (gastric) adenocarcinoma, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma, confirmed by lab testing of tissue or cells, and who have already received one prior treatment (first-line therapy) - People whose ca...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06446726 · Sichuan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a specific type of esophageal cancer (squamous cell carcinoma) located in the chest area, confirmed by a tissue biopsy, at a stage that has not spread to distant parts of the body - Your doctors believe surgery could completely remove the cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06447064 · Imperial College London Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2027
🇬🇧 GB

**Who might be able to join this trial:** - You must be 18 years of age or older - You must be living in the United Kingdom at the time you sign up for the trial - You must be registered with an NHS GP practice - You must fall into one of two groups: either you have been diagnosed with one of the following cancers in...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06452602 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to participate and attend follow-up visits - Adults aged 18 or older, of any gender - People diagnosed with locally advanced squamous cell cancer of the oesophagus, confirmed by tissue biopsy, at a specific stage of disease (cT1N2-3M0, cT2-4bN0-3M0, or...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06463834 · Fujian Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 19 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are aged between 18 and 75 years old - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of esophageal cancer) confirmed by a tissue biopsy - People whose cancer is located in the middle section of the esophagus and has been st...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06469944 · Merck Sharp & Dohme LLC Phase 2 · 12 countries Recruiting
Recruiting Phase 2 Est. completion 12 September 2029
🇧🇷 BR🇨🇱 CL🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇳🇴 NO🇰🇷 KR +4 more

**Who might be able to join this trial:** - People who have a confirmed diagnosis (through biopsy or lab testing) of locally advanced, inoperable, or metastatic stomach or esophageal adenocarcinoma (a specific type of cancer) that has not yet been treated - People whose cancer is not expected to need surgical removal...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06474468 · Shanghai Hengrui Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to understand and sign a consent form and are willing to follow the trial's treatment plan and visit schedule - People aged 18 to 70 years old, of any gender - People who can provide a stored or fresh tumour tissue sample for testing - People who have at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06476067 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2028
🇯🇵 JP

**Who might be able to join this trial:** - You have been diagnosed with esophageal squamous cell cancer (a specific type of cancer in the food pipe), confirmed by a tissue test. - You had surgery to fully remove the esophagus along with nearby lymph nodes, and did not receive chemotherapy or radiation therapy before o...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06476678 · Baylor College of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

Who might be able to join this trial: - People who are older than 18 years of age - People who are able to give their informed consent to participate - People who have been referred to have a precancerous growth removed, where the growth is a mucosal-based polyp (a growth on the inner lining of the digestive tract), lo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06490003 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2026
🇯🇵 JP

Who might be able to join this trial: - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed through a tissue sample test. - People who have already undergone chemotherapy treatment. - People who are at the beginning of their chemotherapy treatm...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06498752 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who have been confirmed through a tissue or cell sample to have squamous cell carcinoma (a specific type of cancer) of the esophagus (food pipe), at a stage where surgery is not possible (initial stage I–VIa) - People with a ge...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06509568 · Zhejiang Cancer Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are male or female, aged 18 to 75 years old at the time of signing the consent form. - People who are in good enough general health to carry out daily activities, as measured by standard medical scoring tools (ECOG score of 0–1, or Karnofsky score of 80 or above)....

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06510543 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - Be between 18 and 80 years old - Be in good enough general health to be reasonably active (confirm with trial site what this means for your situation) - Have been identified as being at nutritional risk based on a standard screening tool score (confirm with trial site) - Hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06510660 · Fujian Medical University Union Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 70 years, of any gender - People who have not yet received any treatment (systemic or local) for their cancer - People with a confirmed diagnosis of squamous cell carcinoma of the esophagus at a specific stage (stages II to IVA, or stage IVB with cancer spr...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06515964 · Changhai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - You are a man or woman between 18 and 85 years old - You had a procedure called ESD (a type of endoscopic surgery) to remove an early-stage squamous cell cancer in the esophagus (food pipe), and this procedure was done following standard medical guidelines - After the ESD pro...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06523374 · University Hospital, Antwerp Not Applicable · 6 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇧🇪 BE🇩🇰 DK🇫🇷 FR🇮🇪 IE🇮🇹 IT🇸🇪 SE

**Who might be able to join this trial:** - People who have a known condition called Barrett's oesophagus (a change in the lining of the food pipe) and are scheduled for a procedure to investigate or treat a suspected early cancer in the food pipe using a technique to remove tissue (EMR or ESD) - People who are able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06531434 · National Cheng-Kung University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer), confirmed by laboratory testing of tissue samples - People whose cancer has grown into nearby organs (known as T4 stage disease) - People aged between 18 and 70 years o...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06532734 · Denver Health and Hospital Authority Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with an eating disorder that includes a history of purging (such as self-induced vomiting or similar behaviors) - You are between 18 and 65 years old - You have had a history of purging for 5 years or more - At the time of admission, you are purging or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06545331 · Exelixis Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 23 November 2026
🇬🇧 GB🇺🇸 US

Who might be able to join this trial: - You must be 18 years of age or older at the time you sign the consent form - You must be fairly active and able to carry out daily activities with little or no limitations (this is measured by a standard scale doctors use called ECOG, scored 0-1) - Your liver, kidneys, bone marro...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06558786 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 August 2029
🇺🇸 US

**Who might be able to join this trial:** - People who have been newly diagnosed with stage IV adenocarcinoma (a type of cancer) of the esophagus (food pipe) or the gastroesophageal junction (where the food pipe meets the stomach), with a limited number of cancer spread sites at the time of first diagnosis - People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06561178 · Sun Yat-Sen University Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have operable, locally advanced squamous cell carcinoma (a type of cancer) of the esophagus (the tube connecting the throat to the stomach) - People who have already received a combination of chemotherapy and radiation therapy (with or without immunotherapy) before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06563869 · The First Affiliated Hospital with Nanjing Medical University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 22 November 2025
🇨🇳 CN

Who might be able to join this trial: - People who have agreed to take part voluntarily and have signed a consent form - Adults aged 18 to 75 years old (male or female) - People diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue biopsy, with no spread...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06569459 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 November 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, have signed a consent form, and are able to follow the study requirements - Adults aged 18 or older, of any gender - People who have been diagnosed through a tissue biopsy with locally advanced esophageal squamous cell carcino...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06576973 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have signed a consent form agreeing to take part in the study - People aged between 18 and 75 years old - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue sample (biopsy) - Peopl...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06586242 · Xijing Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People whose biopsy (tissue sample taken during a stomach camera procedure) has confirmed esophageal cancer, with a specific stage of disease classified as Stage II to Stage IVA (based on how far the cancer has grown and whethe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06594744 · Taipei Veterans General Hospital, Taiwan Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 October 2030
🇹🇼 TW

**Who might be able to join this trial:** - People who have liver cancer (called HCC) and also have high-risk enlarged veins in the esophagus (the tube connecting the throat to the stomach), confirmed by imaging and clinical information, classified as a moderate or severe level using a standard medical grading system (...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06596954 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and able to sign a consent form showing you understand the trial - You have been diagnosed with esophageal squamous cell carcinoma (a specific type of esophageal cancer) confirmed by a tissue test - Your cancer is locally advanced, meaning it has...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06597240 · University Medical Center Groningen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇳🇱 NL

Who might be able to join this trial: - You are 18 years of age or older at the time of signing the consent form - You have been diagnosed with a specific type of cancer (adenocarcinoma, squamous cell carcinoma, or mixed type) of the oesophagus (food pipe) or the area where the food pipe meets the stomach, confirmed by...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06602843 · Anhui Provincial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have had surgery to fully remove esophageal cancer (a complete, curative surgery — not just partial removal) - Lab results from your surgery confirmed your cancer type is esophageal squamous cell carcinoma (a specific type of esophage...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06603402 · Sichuan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2025
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 80 years - People who have been diagnosed with locally advanced, inoperable esophageal squamous cell cancer (a type of throat/food pipe cancer) and have completed a full course of treatment aimed at curing it, such as chemotherapy combined with radi...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06618742 · Laura Boer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2025
🇳🇱 NL

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing consent - You have been diagnosed with esophageal or gastroesophageal (where the esophagus meets the stomach) cancer, confirmed by a tissue sample - You are receiving care focused on managing symptoms and quality of life...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06623396 · Memorial Sloan Kettering Cancer Center Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2028
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People who have been diagnosed with esophageal or gastroesophageal junction (EG) adenocarcinoma, confirmed by a tissue test (pathology) - People whose cancer has spread to other parts of the body (metastatic) or has come back after previous treatmen...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06637163 · Shanghai Zhongshan Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇨🇳 CN

Who might be able to join this trial: - People who are willing to take part voluntarily and agree to follow the study requirements by signing a consent form. - People aged 18 or older, of any gender. - People who are generally well enough to carry out daily activities with little or no limitation (based on a standard h...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06644781 · Daiichi Sankyo Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 1 June 2028
🇧🇪 BE🇨🇳 CN🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP🇳🇱 NL🇵🇱 PL +5 more

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with esophageal squamous cell cancer (a type of throat/food pipe cancer) that cannot be removed by surgery and has either spread to nearby areas or to other parts of the body, confirmed by a tissue or cell sample - Your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06646588 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and have given written consent to participate - People aged 18 or older, of any gender - People who have been confirmed through tissue or cell testing to have limited-stage small cell lung cancer (meaning the cancer has not spread to dista...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06657144 · Coherus Oncology, Inc. Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 1 January 2028
🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** **Criteria that apply to all groups:** - People who have at least one tumour that can be measured using standard imaging criteria. - People whose side effects from any previous cancer treatment have mostly resolved or are only mild. **Group A – Second-line treatment for stoma...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06663059 · Tang-Du Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have given written consent and are willing to take part in the study voluntarily. - People whose esophageal cancer has been confirmed by laboratory testing of tissue or cell samples as squamous cell carcinoma. - People whose cancer is located in the chest portion of th...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06675201 · Sichuan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years old - People who have been diagnosed with locally advanced, inoperable esophageal squamous cell cancer (a type of throat/food pipe cancer) and have already completed a full course of treatment aimed at curing the cancer (such as chemotherapy combin...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06676449 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 October 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are aged between 18 and 75 years old - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of throat/food pipe cancer) confirmed by a tissue sample test - People whose cancer has been staged at a certain level based on standard...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06684600 · Peking University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 75 years old, of any gender. - People who have been confirmed by laboratory tissue testing to have esophageal squamous cell carcinoma (a specific type of oesophageal cancer) that has come back or spread to other parts of the body. - People whose cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06687603 · Case Comprehensive Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 September 2028
🇺🇸 US

Who might be able to join this trial: - Adults who have not had a scope procedure to look at the inside of their oesophagus and stomach (called an EGD or upper endoscopy) in the past ten years - People who are able to read, understand, and sign a written consent form agreeing to take part - People who do not have a kno...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06687876 · Amsterdam UMC, location VUmc Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇳🇱 NL

**Who might be able to join this trial:** - You have been diagnosed with a specific type of cancer (adenocarcinoma) of the oesophagus (food pipe) or the area where the oesophagus meets the stomach, confirmed by a tissue test, and the cancer has not spread too far and can be removed by surgery. - You are planning to re...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06690476 · Peking University Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are able to give written consent and are willing to follow the study schedule and requirements. - Adults aged 18 or older, of any gender. - People who have been confirmed through a tissue sample (biopsy) to have a specific type of esophageal cancer called squamous...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06695845 · Jazz Pharmaceuticals Phase 2 · 3 countries Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇰🇷 KR🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You must be at least 18 years old - You have an advanced, spreading, or inoperable solid tumour (not gallbladder cancer or bile duct cancer) that has continued to grow after at least one previous cancer treatment, and no other proven treatment options are available — or you...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06709417 · Shanghai Chest Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have given written consent before any study procedures begin - People aged between 20 and 75 years, of any gender - People diagnosed with a specific type of oesophageal cancer called squamous cell carcinoma, confirmed by tissue biopsy and imaging, at a locally adv...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06710665 · Fujian Medical University Union Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

Who might be able to join this trial: - People who had surgery to completely remove their esophageal cancer, with no cancer left behind, and had lymph nodes removed from two or three areas of the body during that surgery - People who received treatment before their surgery, such as radiation therapy, chemotherapy combi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06713421 · Changhai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are aged 18 to 70 years old (male or female) - People who are willing to take part voluntarily and sign a consent form **Who may not be able to join:** - People who have active bleeding in their stomach or intestines - People who have a narrowing of the oesophagus...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06713993 · Semmelweis University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2029
🇭🇺 HU

Who might be able to join this trial: - People who are over 18 years old - People who have been recently diagnosed with a new tumour of the oesophagus (food pipe) or the area where the oesophagus meets the stomach - People who are scheduled for planned surgery aimed at removing the cancer completely (either open surger...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06715839 · RenJi Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old, of any sex - People who have been diagnosed with a cancer of the digestive system confirmed by tissue testing, or who have imaging scans suggesting a possible digestive system cancer - People who are able to give their signed agreement to participa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06718205 · The First Affiliated Hospital of Zhengzhou University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to participate voluntarily, have signed a consent form, and are able to attend follow-up visits as required. - People who have been confirmed by tissue testing to have esophageal squamous cell carcinoma (a type of oesophageal cancer) that cannot be sur...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06720636 · Erasmus Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2027
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 or older who have been diagnosed with a very long segment of Barrett's esophagus (a condition where the lining of the food pipe changes) - People who are well enough to undergo an endoscopy (a procedure where a camera is passed down the throat to look at the food p...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06732388 · National Cancer Institute (NCI) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2030
🇺🇸 US

**Who might be able to join this trial:** - People who have previously had a scope procedure of the upper digestive tract (a camera examination of the throat, stomach, and upper intestine) that confirmed Barrett's oesophagus measuring at least 2 cm, with either low-grade cell changes, high-grade cell changes, or very...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06747585 · Alentis Therapeutics AG Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 15 February 2028
🇫🇷 FR Hong Kong🇮🇹 IT🇸🇬 SG🇰🇷 KR🇪🇸 ES🇹🇼 TW🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (confirmed by tissue or cell testing) with advanced, inoperable, or metastatic squamous cell cancers in one of these areas: the lungs (SqNSCLC), head and neck including the nasopharynx (HNSCC), oesophagus (ESCC), or skin (CSCC). - For the early...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06748911 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇺🇸 US

**Who might be able to join this trial:** - You are 22 years of age or older, with or without a condition called Barrett's Esophagus (a change in the lining of the food pipe sometimes caused by acid reflux) - You have had a camera examination of your food pipe (called an endoscopy) within the last year - If you have Ba...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06753747 · West China Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years. - People who have been diagnosed with advanced, inoperable squamous cell cancer of the oesophagus (food pipe) that has either come back in nearby lymph nodes or spread to other parts of the body, confirmed by a tissue or cell sample. - Pe...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06755866 · Yunnan Cancer Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇨🇳 CN

Who might be able to join this trial: - People aged 18 years or older. - People who have been newly and first-time diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue biopsy. - People whose cancer is at a certain stage — either an intermediate stage tha...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06769113 · Shanghai Henlius Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 October 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part in clinical research, have fully understood the study, and are willing to sign a consent form and follow all study procedures - People aged 18 to 75 years old at the time of signing the consent form - People who have been diagnosed with es...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06773507 · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed (by tissue or cell testing) with either: (Group 1) esophageal cancer of a specific type (squamous cell carcinoma) that cannot be removed by surgery, has spread locally or to other parts of the body, and standard treatments have not worked or are not a...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06780111 · Merck Sharp & Dohme LLC Phase 2 · 15 countries Recruiting
Recruiting Phase 2 Est. completion 4 January 2032
🇧🇷 BR🇨🇱 CL🇨🇳 CN🇨🇿 CZ🇫🇷 FR🇩🇪 DE🇮🇹 IT🇯🇵 JP +7 more

**Who might be able to join this trial:** - You have been diagnosed with squamous cell carcinoma of the esophagus that has spread or cannot be surgically removed, and you have not yet had treatment for this advanced stage of the disease. - Your cancer can be measured on scans, as assessed by the trial team. - Any side...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06787313 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are aged 18 or older - People who have been diagnosed with esophageal cancer confirmed by tissue testing - People whose cancer is at an advanced stage (Stage IV) or whose esophageal cancer has come back after previous treatment - People whose treatment plan include...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06790797 · Zhao Jun Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with lung cancer or esophageal cancer and have agreed to receive a type of immunotherapy that targets PD-1 or PD-L1 - People aged between 18 and 80 years old - People who are fully active or have only minor restrictions in physical activity (thi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06792786 · The Central Hospital of Lishui City Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇨🇳 CN

Who might be able to join this trial: - People who are willing and able to sign a consent form before any study procedures begin - People aged 18 to 75 years old - People who have been diagnosed with esophageal cancer (specifically the squamous cell type) confirmed by a tissue or cell sample - People whose cancer is at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06803927 · Cyted Health Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are already scheduled to have a standard upper endoscopy (a camera procedure to look at the throat and stomach), with or without a treatment procedure to remove abnormal tissue - People who are willing to have a non-endoscopy tissue sample taken using the study de...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06819566 · Asan Medical Center Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2026
🇰🇷 KR

**Who might be able to join this trial:** - You are between 19 and 79 years old. - Your liver function has been rated as "Child-Pugh Class A," meaning your liver is still functioning reasonably well (confirm with trial site). - You have been diagnosed with advanced liver cancer (Barcelona Clinic Liver Cancer stage C) a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06824363 · University of California, Irvine Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - People who have cancer of the esophagus or stomach (including cases that cannot be surgically removed) that has not spread to other parts of the body - People who have not yet received any treatment for this cancer - People whose cancer has been confirmed by a laboratory test to...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06829095 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2025
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with esophageal cancer or head and neck cancer, confirmed by laboratory tissue testing and CT scan - People who are receiving combined chemotherapy and radiation treatment (CCRT) for their cancer - People whose overall health and ability to carry ou...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06840704 · Hunan Cancer Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part, understand what the study involves, and are able to sign a written consent form. - People aged 18 or older. - People who have been diagnosed with lung cancer (either non-small cell or small cell lung cancer), confirmed through a tissue or...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06843889 · Nanfang Hospital, Southern Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years old, of any sex - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by tissue testing - People with thoracic (chest) oesophageal cancer at a specific stage (T2–4a, N0–3, M0 according...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06869213 · Peking University Cancer Hospital & Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years old, of any gender - People diagnosed with locally advanced squamous cell carcinoma of the esophagus (a specific type of esophageal cancer), confirmed by lab testing, that doctors have assessed as surgically removable and at a particular stage of s...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06869226 · Peking University Cancer Hospital & Institute Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part, have signed a consent form, and are able to attend follow-up appointments - You have been diagnosed with esophageal cancer confirmed by a tissue biopsy, at a specific stage that has not spread to distant parts of the body (confirm with trial sit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06872515 · University of Pittsburgh Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇺🇸 US

Who might be able to join this trial: - You are a man or woman aged 18 or older - You have been diagnosed with esophageal cancer - You have been identified as a candidate for esophagus removal surgery (esophagectomy) at Hillman Cancer Center, UPMC Shadyside, or UPMC Passavant - Your surgery is scheduled at least 2 week...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06885814 · Nanfang Hospital, Southern Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 75 years old (any gender) - You have been diagnosed with esophageal squamous cell carcinoma (a specific type of esophageal cancer) confirmed by a tissue test, and the cancer either cannot be surgically removed or has come back after surgery - You have...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06906887 · Medical College of Wisconsin Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2030
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older - People diagnosed with Stage II to IVb adenocarcinoma (a type of cancer) of the esophagus — if Stage IVb, only those with a small number of spread sites (called oligometastatic), where the treating doctor considers a full-dose chemotherapy and radiat...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06907602 · Peking Union Medical College Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have had their esophageal squamous cell carcinoma (a type of throat/food pipe cancer) confirmed by a laboratory test - People whose cancer has been assessed by scans (ultrasound, CT, and MRI) as being at a specific stage —...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06912074 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 4 April 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with esophageal squamous cell carcinoma (a type of throat/food pipe cancer) confirmed by a laboratory test on a tissue or cell sample - People whose cancer has been assessed as unable to be removed by surgery, is locally advanced, and falls within a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06943521 · Tanabe Pharma America, Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 1 August 2028
🇯🇵 JP🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older at the time of signing the consent form - People whose cancer has at least one measurable area of disease, as seen on scans (using a standard measurement method called RECIST v1.1) - People who have already tried at least one prior cancer treatment, a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06964568 · Fudan University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2029
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to give written consent to participate - You are 18 years old or older - You have been diagnosed with esophageal squamous cell carcinoma (a specific type of throat/food pipe cancer) confirmed by a tissue sample (biopsy) - Your cancer is at a certain s...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06975410 · Yuhan Corporation Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2027
🇰🇷 KR

**Who might be able to join this trial:** - You must be willing and able to sign a consent form before any study procedures begin. - You must be generally well enough to carry out daily activities with little or no limitation (this is measured by a standard health scale called ECOG 0 or 1 — confirm with trial site). -...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06979869 · Xijing Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2030
🇨🇳 CN

**Who might be able to join this trial:** - People who were between 18 and 75 years old (inclusive) when they were first diagnosed with their cancer - People who have been diagnosed with esophageal cancer (cancer of the food pipe) confirmed by a tissue biopsy, with complete medical records including a pathology report...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06988956 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part, have signed a consent form, and are able to attend follow-up appointments - You are aged 70 or older (any gender) - You are generally active and able to care for yourself, with only mild limitations on physical activity (confirm with trial site)...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07001592 · Allegheny Singer Research Institute (also known as Allegheny Health Ne... Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 April 2028
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 69 years old at the time of signing the consent form - You have been diagnosed with cancer that started in the digestive system (such as the colon, stomach, or intestines) that has spread to other parts of the body, and your tumor has been tested for specif...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07004634 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 years or older - People who have been diagnosed with esophageal cancer (confirmed through laboratory testing of tissue) and whose treatment plan requires a specific type of surgery involving three separate cuts — in the neck, chest, and abdomen - People who have be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07021066 · SystImmune Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 28 February 2027
🇺🇸 US

Who might be able to join this trial: - People aged 18 or older who have voluntarily agreed to take part and follow the study requirements - People with a life expectancy of at least 3 months - People with a locally advanced or metastatic solid tumour that has come back or kept growing after at least one round of prior...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07024849 · Samsung Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇰🇷 KR

**Who might be able to join this trial:** - People diagnosed with primary esophageal cancer at stage 1, 2, or 3, who have had or are planning to have surgery to remove and reconstruct the esophagus as part of treatment aimed at curing the cancer — as well as their family members - People who are at least 18 years old -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07035587 · Yonsei University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 July 2029
🇰🇷 KR

**Who might be able to join this trial:** - People aged 19 years or older - People who have agreed to take part voluntarily and have signed a consent form - People who are able to give a blood sample safely - People (in the cancer group) who have had or are planned to have surgery or chemotherapy to treat their cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07038629 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part and attend follow-up visits - People aged 70 or older, of any gender - People who have been diagnosed with locally advanced squamous cell cancer of the oesophagus (a specific type and stage of oesophageal cancer), confirmed by a tissue bio...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07039162 · Ming-Yu Lien Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇹🇼 TW

**Who might be able to join this trial:** - People who have been diagnosed with squamous-cell carcinoma of the oesophagus (a specific type of oesophageal cancer), confirmed by a tissue biopsy - People whose cancer has been classified as a locally advanced stage, meaning the tumour has grown into a nearby organ, nearby...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07039526 · John Waters Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have been diagnosed with, or are strongly suspected to have, a cancer affecting the digestive system, pancreas, liver and bile ducts, oesophagus, or gynaecological organs, and where a specific surgical procedure (HIPEC/debu...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07043491 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 July 2025
🇨🇳 CN

Who might be able to join this trial: - People who have already had either an endoscopy (a camera examination of the inside of the digestive tract) or an esophagram (an X-ray test of the swallowing tube) as part of their routine follow-up care after surgery to check how the surgical join healed. Who may not be able to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07050576 · The First Affiliated Hospital of Anhui Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with early-stage esophageal cancer (specifically stage T1) that has been confirmed by a laboratory test on a tissue sample - You had a detailed CT scan (with contrast dye) taken within 2 weeks before your surgery - You have not received any treatment b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07054086 · Shanghai Zhongshan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇨🇳 CN

**Who might be able to join this trial:** - A tissue sample taken during an endoscopy must have confirmed a specific type of oesophageal cancer called squamous cell carcinoma. - The cancer must be located in the part of the oesophagus that runs through the chest area. - Scans and tests (such as CT, ultrasound, PET-CT,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07059884 · Alliance for Clinical Trials in Oncology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with one of the following cancers (confirmed by laboratory testing): anus, bladder, breast, cervix, colon/rectum, endometrium, esophagus, gallbladder, head/neck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, or stomach. - People who are s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07063901 · Central South University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with esophageal cancer that was confirmed through a tissue sample (biopsy) - People for whom a team of specialists, or a thoracic (chest) surgery specialist, has recommended a combination of chemotherapy and immunotherapy before any surgery - People...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07071103 · Chuangzhen Chen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 years, of any gender - People who are reasonably active and able to care for themselves, or who need only limited help with daily activities (this is measured using a standard scale called ECOG, levels 0–2) - People with a life expectancy of more than 3 m...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07080437 · Three Gorges Hospital of Chongqing University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are joining this trial of your own free will and have signed a consent form agreeing to take part - You are aged 70 years or older (any gender) - You have been diagnosed with esophageal squamous cell cancer (a type of food pipe cancer), confirmed by a tissue or cell sampl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07085091 · ALX Oncology Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with one of the following cancers (confirmed by a tissue sample): head and neck cancer (HNSCC), non-small cell lung cancer (NSCLC), oesophageal squamous cell cancer (ESCC), or colorectal cancer (CRC), and the cancer has spread or come back and cannot...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07086469 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 19 July 2029
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed through laboratory testing of tissue or cell samples. - People whose cancer is locally advanced and cannot be surgically removed, based on scans and imaging, a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07088354 · Tongji Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a laboratory test on a tissue sample. - People who have received at least one round of pre-surgery treatment combining chemotherapy and immunotherapy...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07102901 · Jiangsu HengRui Medicine Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are 18 years old or older (or the minimum legal adult age in your country) at the time you sign the consent form. - You have at least one tumor that can be measured by a CT or MRI scan, as confirmed at the screening stage. - You are willing to provide a tissue sample from...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07104214 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2026
🇨🇳 CN

Who might be able to join this trial: - You must be 18 years old or older. - You are already scheduled to have a planned (non-emergency) stomach scope or combined stomach and bowel scope procedure done under sedation. - You are willing and able to give your consent to take part in the trial. Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07109726 · Terremoto Biosciences Inc. Phase 2 · 2 countries Recruiting
Recruiting Phase 2 Est. completion 30 December 2028
Puerto Rico🇺🇸 US

Who might be able to join this trial: - People who have cancer that has spread to other parts of the body or has grown in a way that cannot be surgically removed, and for which no treatment aimed at curing the disease is available. - People whose cancer shows specific changes (alterations) in a biological pathway calle...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07132918 · University of Wisconsin, Madison Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - You must be 18 years of age or older at the time of signing the consent form. - Based on a quick automated planning scan, a certain amount of radiation would reach your heart (specifically, more than 10% of your heart would receive more than 25 Gray units of radiation) — (con...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07152678 · National Taiwan University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇹🇼 TW

Who might be able to join this trial: - Adults between 18 and 85 years of age who are reasonably functional in daily life (a doctor would assess this using a standard scale called ECOG, scoring 0 to 2) - People diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma that has spre...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07162506 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and able to attend follow-up appointments - You are between 18 and 75 years old (male or female) - You have been diagnosed with esophageal squamous cell cancer (a type of throat/food pipe cancer) that has been confirmed by a tissue sample, is at...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07165184 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 July 2027
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with a specific type of esophageal (food pipe) cancer called squamous cell carcinoma - People whose cancer has been staged at a certain level, meaning the tumor is within a specific size and spread range, has not spread to distant parts of the body,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07165210 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 21 July 2027
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with a specific type of esophageal (food pipe) cancer called squamous cell carcinoma - Your cancer is at a certain stage, meaning it has not spread to distant parts of the body (confirm with trial site for exact staging details) - You have not had any othe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07175155 · Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 August 2027
🇨🇳 CN

Who might be able to join this trial: - People who are 18 years of age or older - People with a body mass index (BMI) of 35 or higher (a measure of body weight relative to height) - People who are already scheduled to have a gastroscopy or gastrointestinal endoscopy (a procedure where a thin, flexible camera is used to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07177794 · Sun Yat-sen University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 May 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with squamous cell carcinoma of the esophagus, confirmed through a tissue biopsy - People whose cancer was classified as stage I to IVA (where surgery was not possible or was declined) or stage IVB esophageal cancer that had spread only to lymp...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07181473 · Phrontline Biopharma Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 30 December 2026
🇨🇳 CN🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with advanced or metastatic solid tumour cancer (confirmed by tissue or cell testing) whose cancer has stopped responding to standard treatments, or for whom no standard treatment exists. - People who have at least one tumour that can be measur...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07182149 · Normunity AccelCo, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 May 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed (through a tissue or cell sample) with one of the following advanced or metastatic cancers: non-small cell lung cancer (squamous or adenocarcinoma type), triple-negative breast cancer, head and neck squamous cell cancer, esophageal squamous cell...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07187154 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - You are awake, aware, and able to communicate in Mandarin - You own and use a smartphone - You are comfortable using WeChat mini programs (small apps within WeChat) - You are scheduled to have surgery to remove esophageal cancer at one of the participating hospitals Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07188103 · Anhui Provincial Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 80 who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by laboratory testing of tissue samples - People whose cancer cannot be surgically removed, has come back after surgery, or has spread to ot...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07205731 · University Hospital, Clermont-Ferrand Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2029
🇫🇷 FR

**Who might be able to join this trial:** - You have been confirmed by a tissue biopsy to have a type of esophageal (food pipe) cancer called squamous cell carcinoma - Your cancer has spread to other parts of the body or is at an advanced local stage - You have not yet received any treatment (such as immunotherapy, ch...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07217704 · SOFIE Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 30 August 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older (male or female) - You have been diagnosed with stomach cancer, esophageal cancer, or cancer at the junction of the stomach and esophagus, and are currently being assessed to plan your treatment - You are reasonably active and able to care for you...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07251114 · Fujian Provincial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇨🇳 CN

Who might be able to join this trial: - People who are over 18 years old - People who have records from an endoscopy (a camera examination of the inside of the throat and stomach) and detailed pathology (tissue test) results - People who have agreed to take part in the study - People who also have at least one of the f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07264036 · Vanessa Torrecillas Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who speak English - People who have a history of head and neck cancer that was treated with surgery, radiation combined with chemotherapy, or both - People whose speech has been assessed by a clinician and found to have a quality called hypernasality, wher...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07266363 · City of Hope Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 18 June 2026
🇺🇸 US

Who might be able to join this trial: - You are between 18 and 90 years old - You have been diagnosed with a specific type of esophageal (food pipe) cancer called squamous cell carcinoma, confirmed through a tissue sample test - You have not received any previous drug-based cancer treatments before your sample is colle...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07266480 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have been diagnosed with a specific type of oesophageal cancer (squamous cell cancer in the chest area of the oesophagus), confirmed by tissue testing, at a particular stage of disease (confirm with trial site for stage det...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07266493 · Shanghai Zhongshan Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and are able to sign a consent form - People aged 18 or older at the time of signing the consent form - People who have a good level of daily functioning (rated 0 or 1 on a standard medical scale that measures how much a condit...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07272382 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 5 June 2027
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older who are well enough to carry out daily activities (assessed using a standard medical scale called ECOG, with a score of 0, 1, or 2) - People with esophageal (food pipe) cancer that has come back or spread, confirmed through a tissue sample, including those...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07290010 · Hebei Medical University Fourth Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - Adults aged 18 or older, of any gender - People with unresectable, recurrent, or advanced spreading esophageal squamous cell carcinoma (a specific type of esophageal cancer) confirmed by laboratory tissue testing — certain mixed or other cancer types are not included - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07309991 · Sun Yat-sen University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with esophageal cancer or a non-cancerous tumour of the oesophagus (the tube connecting the throat to the stomach) - People whose condition requires surgery to remove the affected area, followed by reconstruction of the oesophagus - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07317609 · Shanghai Zhongshan Hospital Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 30 September 2027
🇨🇳 CN

**Who might be able to join this trial:** This trial has two groups (Cohort A and Cohort B). Please check which group may apply. **Cohort A – Esophageal cancer that may be removable by surgery:** - People between 18 and 80 years old. - People who have been diagnosed with a specific type of esophageal cancer called s...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07322627 · National Taiwan University Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 October 2027
🇹🇼 TW

**Who might be able to join this trial:** - People who have been diagnosed with esophageal cancer (cancer of the food pipe) confirmed through laboratory testing of tissue samples, and who have previously signed a consent form agreeing to allow leftover samples to be used in future studies. **Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07339488 · Chuangzhen Chen Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 November 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily, agree to follow the study requirements, and sign a consent form - People aged 18 to 75 years (any sex) - People whose general health and ability to carry out daily activities falls within a certain range, as measured by a stan...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07354295 · Shu Peng Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2030
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with esophageal cancer that has been confirmed by a laboratory test of tissue samples. - You have complete background health information available from before treatment started, including details about your general health status and how far the cancer...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07355374 · University Hospital, Basel, Switzerland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2028
🇨🇭 CH

Who might be able to join this trial: - Adults aged over 18 years - People who have been diagnosed with esophageal (food pipe) cancer, confirmed through a tissue sample test - People whose treatment plan includes a specific type of keyhole surgery called a minimally invasive Ivor Lewis procedure, with the aim of removi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07359417 · UMC Utrecht Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 May 2028
🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, or the same type of cancer at the junction where the food pipe meets the stomach (a specific position called Siewert type I or II), confirmed through a tissue sam...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07367516 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged between 18 and 75 years old (inclusive) - People who are willing to take part, sign a consent form, and follow the study requirements - People with a good general activity level, rated 0 or 1 on a standard oncology performance scale (this measures how much cancer...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07375420 · University of Surrey Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇬🇧 GB

Who might be able to join this trial: - You are an adult (18 or older) with a type of oesophageal (food pipe) cancer called adenocarcinoma that can be removed by surgery - You are planned to receive chemotherapy before your surgery (called neoadjuvant chemotherapy) Who may not be able to join: - You are unable to do a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07385001 · Tang-Du Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 28 January 2027
🇨🇳 CN

Who might be able to join this trial: - People who have given written consent before any study procedures begin. - People aged between 18 and 75 years old (inclusive), of any gender. - People who have been confirmed through a tissue sample (biopsy) to have a specific type of esophageal (food pipe) cancer called squamou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07399652 · Asian Institute of Gastroenterology, India Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2026
🇮🇳 IN

Who might be able to join this trial: - You have been diagnosed with Achalasia Cardia (a condition affecting the food pipe/swallowing) or a tumour/growth (neoplasm) Who may not be able to join: - You have a health condition that makes a specific type of internal procedure (called third space endoscopy) unsafe or unsui...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07403136 · Fudan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 August 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to sign a consent form and follow the study requirements. - People who are 18 years of age or older at the time of signing the consent form, of any gender. - People who are expected to live for at least 12 weeks. - People who have been confirmed by tis...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07405151 · Merck Sharp & Dohme LLC Phase 2 · 10 countries Recruiting
Recruiting Phase 2 Est. completion 12 June 2027
🇧🇷 BR🇨🇳 CN🇨🇿 CZ🇯🇵 JP🇳🇴 NO🇰🇷 KR🇨🇭 CH🇹🇼 TW +2 more

**Who might be able to join this trial:** - You have been diagnosed with a type of esophageal cancer called squamous cell carcinoma that cannot be removed by surgery and has either spread locally or to other parts of the body (confirmed by a biopsy or cell test) - Your cancer has gotten worse after trying 1 or 2 previo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07410676 · Essen Biotech Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 21 December 2028
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older - People with an advanced or metastatic solid tumour (a cancer that has spread) that has been confirmed by laboratory testing of tissue, and that has come back or stopped responding to standard treatments — or where no standard treatment exists - Peop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07426835 · Royal College of Surgeons, Ireland Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇮🇪 IE

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with oesophageal cancer (cancer of the food pipe) - Your doctors have planned for you to have a robotic surgery to remove part of your oesophagus, with the aim of curing the cancer - There is no sign from scans or tests that...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07435454 · Jiangsu Cancer Institute & Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed through a tissue biopsy with esophageal squamous cell carcinoma (a specific type of esophageal cancer) that has spread to nearby lymph nodes or grown into surrounding tissue, but has not spread to distant parts of the body, and cannot be surgic...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07437898 · The Affiliated Hospital of Putian University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to join the study - You are between 18 and 75 years old (male or female) - You have been diagnosed with a specific type of esophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07449208 · Memorial Sloan Kettering Cancer Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 February 2029
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with a confirmed cancerous tumour of the oesophagus (food pipe) that requires surgical removal of part or all of the oesophagus. - People who have one or more risk factors that increase the chance of a complication called an anastomotic leak (where...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07452601 · Tang-Du Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 25 February 2027
🇨🇳 CN

Who might be able to join this trial: - People who have read and signed a consent form and agreed to take part in the study voluntarily. - People whose cancer has been confirmed as esophageal squamous cell carcinoma through a tissue or cell sample test. - People whose cancer is located in the chest portion of the esoph...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07455019 · The First Affiliated Hospital with Nanjing Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 April 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and agree to follow the study schedule and attend follow-up appointments - People aged 18 or older (any gender) - People diagnosed through imaging with oligometastatic esophageal squamous cell carcinoma — meaning a type of esop...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07457528 · Tianjin Medical University Cancer Institute and Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 30 June 2027
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years, of any gender - People whose biopsy has confirmed a specific type of oesophageal cancer (squamous cell carcinoma) located in the chest portion of the oesophagus, at a locally advanced stage (confirm with trial site for exact staging details) - Peo...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07463573 · Qilu Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 5 June 2028
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 or older, of any gender - People who are willing to take part and able to sign a consent form agreeing to join the study - People whose general health and activity level is rated as 0 or 1 on a standard oncology scale (meaning fully active or able to carry out...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07464470 · Blokhin's Russian Cancer Research Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2028
🇷🇺 RU

**Who might be able to join this trial:** - Adults aged 18 or older who are already enrolled in a related study called GASTROBRAIN, with medical records and treatment history available. - People who have been diagnosed with stomach cancer (gastric adenocarcinoma), esophageal cancer (either of two specific types), or ca...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07481058 · Beijing Konruns Pharmaceutical Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇨🇳 CN

Who might be able to join this trial: - People aged 18 to 75 years, of any sex - People whose cancer of the esophagus (food pipe) or the junction between the esophagus and stomach has been confirmed by a laboratory test of tissue or cell samples, and is specifically the squamous cell type - People who have not yet rece...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07482566 · Nurettin Şahin Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2028
Turkey (Türkiye)

**Who might be able to join this trial:** - People aged between 18 and 90 years old - People who have been diagnosed with a specific type of cancer at the junction where the oesophagus meets the stomach (called a gastroesophageal junction cancer, Siewert type II or III), confirmed through a tissue sample analysis - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07519486 · Sichuan University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2027
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of oesophageal cancer) confirmed by laboratory testing - People aged between 18 and 80 years, of any gender - People whose general physical condition is rated as reasonably functional (on...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07519655 · Pfizer Phase 1 · 2 countries Recruiting
Recruiting Phase 1 Est. completion 14 July 2028
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of cancer — either non-small cell lung cancer (NSCLC), oesophageal squamous cell carcinoma (ESCC), or skin melanoma — that has spread to other parts of the body or cannot be surgically removed - People whose cancer has conti...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07530094 · Ning Jiang, M.D./Ph.D. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - The patient, or their legal representative, is able to sign a consent form and agrees to follow the study's requirements - People aged 18 to 74 years old at the time of signing the consent form, of any gender - People who have been diagnosed with esophageal squamous cell car...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07554456 · Sichuan Baili Pharmaceutical Co., Ltd. Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 December 2028
🇨🇳 CN

Who might be able to join this trial: - People who are willing to sign a consent form and agree to follow the study's requirements - People of any gender are eligible - People aged 18 to 75 years old at the time of signing the consent form - People with a life expectancy of at least 3 months - People diagnosed with eso...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07554521 · BeOne Medicines Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2031
🇺🇸 US

**Who might be able to join this trial:** - You identify as a member of a racial or ethnic minority group as defined by the FDA, such as Black or African American, Hispanic or Latino, American Indian or Alaska Native, or Native Hawaiian or Other Pacific Islander - You have been diagnosed with advanced stomach cancer,...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07559045 · Second Affiliated Hospital of Zunyi Medical University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue or cell sample, that cannot be removed by surgery and is at stage III or IVA - People who are generally well enough to carry out light a...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07561840 · Kansai Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2029
🇯🇵 JP

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with cancer of the oesophagus (food pipe) or stomach - People who have had surgery aimed at fully removing the cancer - People who are between 4 and 8 weeks after their surgery at the time of joining - Peopl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07578571 · Immunome, Inc. Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 1 January 2029
🇺🇸 US

**Who might be able to join this trial:** - You are generally able to carry out some or all of your usual daily activities (your doctor will have rated your physical fitness on a standard scale as 0, 1, or 2) - For the first part of the trial (Part A): You have been diagnosed with an advanced or spread cancer that can...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07595770 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who have given their written informed consent to participate - Adults aged 18 to 75 years old - People who have been diagnosed with esophageal squamous cell carcinoma (a specific type of cancer of the food pipe) confirmed by a tissue test - People whose cancer has bee...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07596654 · yi shen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with a rare type of esophageal cancer called small cell esophageal carcinoma, confirmed by a tissue or biopsy test. - At the time of diagnosis, your cancer was limited to the esophagus and/or nearby lymph nodes, with no sign of it spreading to other pa...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07617246 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 January 2027
🇨🇳 CN

**Who might be able to join this trial:** - Adults aged 18 or older, of any gender - People who have been diagnosed with locally advanced or metastatic esophageal cancer or lung cancer, confirmed through a tissue or cell sample, and have not yet received treatment for it - People who have never previously received che...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07632079 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 April 2028
🇳🇱 NL

Who might be able to join this trial: - Adults aged 18 years or older. - People with a confirmed diagnosis of oesophageal or gastro-oesophageal junction (GOJ) cancer, based on tissue biopsy results, including specific cancer types such as adenocarcinoma, squamous cell carcinoma, and several others. - People whose tumou...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07638436 · Sun Yat-sen University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 January 2028
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing to take part voluntarily and sign a consent form - People aged between 18 and 75 years old - People who have been confirmed by biopsy to have squamous cell carcinoma (a specific type of cancer) in the chest portion of the food pipe (esophagus), with no...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07671625 · Masaryk Memorial Cancer Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇿 CZ

Who might be able to join this trial: - People who have given their consent to take part in the study - People who are 18 years of age or older - People who have been diagnosed with locally advanced cancer of the oesophagus (food pipe) or stomach that has been identified as needing treatment before and after surgery -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07697859 · Fudan University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 July 2029
🇨🇳 CN

Who might be able to join this trial: - People who are in good general health and are mostly able to carry out daily activities (based on a standard medical performance score of 0 or 1). - People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed thr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07699185 · Tongji Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 July 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who are willing and able to sign a written consent form before any trial procedures begin - Adults aged 18 to 75 years old (male or female) - People who have been diagnosed with a type of oesophageal cancer called esophageal squamous cell carcinoma (ESCC), confirmed b...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Oesophageal Cancer. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

The Pancare Foundation covers oesophageal cancer within its broader work on upper gastrointestinal cancers.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.